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1. Introduction 
1.1 Clinical features 
1.1.1 Epidemiology 
Subarachnoid hemorrhage (SAH), as the name implies, is a disease caused by the 
extravasation of blood into the subarachnoid space which is located between the 
arachnoid mater and the pia mater. SAH is a sub-type of stroke and accounts for 
about 4.4% -9.2%1-3 of all strokes. Although the incidence of SAH varies from region 
to region, the worldwide incidence rate is about 10.5 cases per 100,000 person-years. 
SAH is a devastating neurosurgical emergency which has an in-hospital mortality 
ranging from 18% to 30%4-6. Although the diagnosis and treatment of SAH have 
improved in recent years, our understanding of the pathophysiological processes is 
still limited. Thus until now, no effective therapy is available to decrease the high 
mortality and disability rates. Since most patients need long-term medical 
rehabilitation after SAH, it is a substantial economic burden to health care systems. In 
Germany, the average overall direct cost for SAH treatment in the first year after the 
bleeding is 39,075 € per patient7. Considering the fact that SAH affects mainly 
working individuals (median age 55) and at least 20% of survivors are unable to 
regain functional independence8 9, the indirect socioeconomic burden of SAH makes 
up a great impact on national economics. An incidence-based study in the US in 1992 
estimated that the one-year productivity loss due to aneurysmal subarachnoid 
hemorrhage is about 1,550 billion$ (in 2018 US dollars)10.  
 
Figure 1 
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1.1.2 Etiology 
The cause of SAH varies. It can be caused by brain trauma, cerebral vascular 
malformation, intracranial surgery, central nervous system tumors, pituitary apoplexy, 
cerebral amyloid angiopathy and else11-15. Among non-traumatic SAH, about 85%16 of 
all bleedings are caused by a spontaneous rupture of an intracranial aneurysm. An 
aneurysm is an expansion or bulging in the arterial wall due to a weakening of the 
vessel wall. The incidence of intracranial aneurysm in the general population is about 
3.2%17. Intracranial aneurysms occur more frequently at vessel bifurcations such as 
the circle of Willis18. Intracranial blood vessels have a thick internal elastic lamina but 
little elastin fibers and smooth muscle cells, which make them prone to develop 
aneurysms. The specific pathophysiological mechanism of aneurysm formation is 
unclear. It has been suggested that the formation of intracranial aneurysms depends 
on the degree of vessel wall inflammation, collagen and/or elastin construction and 
hemodynamic stress due to cardiovascular risk factors19 20. 
 
Figure 2 
About 20% of aneurysmal SAH patients have a family history of aneurysm or SAH, but 
the exact genetic factors that cause the formation of intracranial aneurysms are still 
unclear21. Age, female sex and genetic factors are irreversible risk factors for SAH 
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whereas reversible risk factors include cigarette smoking, hypertension, cocaine use, 
and heavy alcohol abuse22.  
1.1.3 Symptoms 
Approximately 10%-43% of aneurysmal SAH patients experience sentinel headache, 
which is possibly caused by enlarging aneurysms or minor bleedings preceding the 
large bleeding. It may occur one to three weeks before the rupture of an aneurysm23 
24.  50% of patients with aneurysmal SAH have instantaneous serious headache, often 
being described as the worst headache in life. Most patients experience nausea (91%), 
vomiting (70%) and physical exertion (50%) together with the onset of headache.25  
Headache after SAH is thought to be caused by increased intracranial pressure (ICP), 
local distention and stretching of intracranial vessel or irritation of adjacent sensory 
nerves by subarachnoid blood (meningeal irritation)26. 35% of patients have neck 
stiffness several hours after the bleeding due to an inflammatory response to blood 
in the subarachnoid space27.  
Impaired consciousness or complete unconsciousness affects around 34%-67% of 
SAH patients. Half of patients experience neurological abnormalities such as a change 
of the mental state or focal neurological deficits which may indicate the location of 
the ruptured aneurysm. For example, a third cranial nerve palsy can be a sign for the 
rupture of a posterior communicating artery aneurysm27 28. Seizures occur in 10%-26% 
of patients during or shortly after SAH and are a risk factor for late seizures and 
related with poor outcome29 30.  
3% of patients complain about blurred vision or floating shadows due to vitreous 
hemorrhage (Terson’s syndrome)31. The generally accepted mechanism is that a 
sudden increase of ICP after SAH induces swelling of the optic disc and occludes the 
retinal venous system, thereby leading to intraocular hemorrhage32. Intraocular 
hemorrhage is often found in patients with impaired consciousness31.  
Systemic symptoms like chest pain, palpitation and dyspnea can be symptoms of 
severe hypertension or hypoxemia. Electrocardiographic changes can be found in 75% 
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of SAH patients without a previously diagnosed heart disease33. About 0.7% of 
patients without previous hypertension had cardiac arrest at onset of SAH, but half of 
the survivors regain self-care ability34.  
1.1.4 Complications 
Rebleeding is an acute and serious complication with an incidence of 8%-23% during 
the first 72 hours, with most of them happening within the first 6 hours after the 
initial bleeding. Rebleedings are associated with a poor prognosis: 20%-60% of 
patients with rebleedings die35.  The clinical manifestation of a rebleeding is the 
exacerbation or reappearance of previous symptoms such as sudden severe 
headache, nausea and vomiting, disturbance of consciousness and convulsions.  
Within the first three days, about 30% of SAH patients develop an acute obstructive 
hydrocephalus due to the formation of a blood clot in the cerebrospinal fluid 
circulation27.  Patients who develop a gradual reduction of consciousness or a sudden 
neurological decline should be examined for hydrocephalus. The clinical presentation 
of a hydrocephalus starts with the reduction of consciousness and eye symptoms 
such as downward deviation and/or small and unreactive pupils. In serious cases, 
patient can develop severe headache, nausea and coma36. 
Delayed cerebral ischemia (DCI) is defined as newly appearing cerebral ischemia or an 
infarction several days after SAH, which cannot be attributed to other identified 
causes. Approximately 30% of SAH patients will develop DCI three to 14 days after 
the onset of aneurysmal rupture37.  DCI is more likely to happen in patients who have 
a large amount of arterial bleeding and/or long duration of initial unconsciousness38 
39. Symptoms of DCI are focal neurological deficit like hemiparesis, aphasia and 
decreased consciousness that can progress due to infarction. It is related with poor 
clinical outcome for SAH patients 40.  
1.1.5 Diagnosis 
Patients who have a classic clinical presentation of SAH with sudden severe headache, 
vomiting and meningeal irritation should be considered to suffer from subarachnoid 
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hemorrhage. Subarachnoid hemorrhage can be confirmed when extravasated blood 
is found in the subarachnoid space on computed tomography (CT) scan41. Various 
studies show that the sensitivity of a non-contrast head CT with at least third-
generation scanners in the hands of an experienced radiologist can reach almost 100% 
within 6 hours of headache onset42. The sensitivity drops to 95% after 6 hours and 
less than 90% after 24 hours43. Apart from the quality of the CT and the radiologist, 
patients who have only small amounts of extravasated blood or a hematocrit below 
30% can have a negative CT scan. Another diagnostic approach is to examine the 
cerebrospinal fluid for the hemoglobin breakdown product bilirubin six to twelve 
hours after onset of headache41. It is absolutely necessary to perform a lumbar 
puncture in every patient who presents with sudden headache and has a negative CT 
scan27.  
Compared to CT imaging, magnetic resonance imaging (MRI) is similarly sensitive, but 
not the first choice in the acute phase after SAH, because CT imaging is faster and 
more cost-efficient. Since the blood signal intensity on CT scan decreases with time, 
MRI is more sensitive for detecting blood between four and 14 days after the initia l 
bleeding44.   
CT angiography is very sensitive for the detection of aneurysm larger than three to 
four mm45. It is recommended by the American Heart Association for suspected SAH 
patients with non-diagnostic non-contrast head CT scan46.  With angiography, the 
number of aneurysm and the adjacent anatomical configuration can be detected, 
which helps doctors to make a better treatment decision. Meanwhile, patients who 
are unfit to undergo lumbar puncture can benefit from angiography42.  
However, with obscure clinical features and/or improper examination method, 12% 
of SAH patients are misdiagnosed. Misdiagnosis is often associated with a high 
mortality and disability rate47. The differential diagnoses for SAH are, e.g. 
hypertensive encephalopathy, meningitis, encephalitis, pituitary apoplexy, mass 
lesion and else42.  
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1.1.6 Therapy 
As soon as the diagnosis of SAH is confirmed, symptomatic treatment as well as 
etiologic treatment aiming at obliterating the aneurysm should be given. 
For general management, patient should be placed in an elevated-head bed for 
better cerebrospinal fluid (CSF) drainage. Continuous observation of vital signs, 
electrocardiographic changes and neurological symptoms are necessary. If patients 
have difficulty in eating, regular food intake can be guaranteed by using a nasogastric 
tube. Establishment of a continuous intravenous access is mandatory. Blood 
electrolyte imbalance and hypo- or hyperglycemia should be corrected, but infusion 
of large amount of hypotonic fluids is not recommended. Analgesia is often needed 
to comfort the patient42. The common agreement for treatment of hypertension is 
that blood pressure should be controlled until the ruptured aneurysm is obliterated46.  
Patients who have a large hematoma might need extensive hemi-craniectomy to 
allow expansion of the brain48. Subdural hematomas should be removed when they 
are life-threatening49.  
Before the final diagnosis of SAH, short-term antifibrinolytics can be given to prevent 
rebleeding. According to a prospective randomized study, immediate administration 
of tranexamic acid can also reduce early rebleeding in SAH patients50. As soon as a 
ruptured aneurysm is confirmed by angiography, experienced specialists’ opinion 
should be considered in choosing surgical clipping or endovascular coiling to 
obliterate the aneurysm46. Patient who received endovascular coiling need follow-up 
cerebrovascular imaging since a compaction of the coil or a recanalization of the 
aneurysm may occur after surgery.  
Hydrocephalus is more common in patients with massive hemorrhage in the peri-
mesencephalic cisterns or with intraventricular blood. After the initial CT scan, 
persistent observation of drowsy patients with dilated ventricles is important since 
spontaneous recovery may happen in up to 50% of patients27. If patients develop a 
symptomatic hydrocephalus, external ventricular drainage is achieved by putting a 
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drainage catheter through a burr hole. Patients with drainage have a risk of 
developing ventriculitis, especially if the catheter remains in place over three days51. 
In any case a strict protocol for handling the drain is necessary. Lumbar drainage may 
also be considered in patients who have a low risk of cerebral herniation46. About 26% 
of SAH patients develop a chronic hydrocephalus and need ventricular shunting 
surgery52. 
Though management of seizures after SAH is disputed, immediate prophylactic 
anticonvulsant agents are usually used after SAH. Patients with preexisting convulsive 
conditions and those who suffered from cerebral infarction, intractable hypertension 
or intracerebral hematoma, long-term use of anticonvulsant agents are usually 
considered46.  
DCI with large artery vasospasm is a primary important contributor to death and 
disability in SAH patients. Thus, constant monitoring of cerebral hemodynamics by 
using transcranial Doppler sonography is inevitable. In addition, CT or MRI scans may 
be useful for identifying potential ischemic lesions46. Clazosentan is an endothelin 
receptor antagonist that prevents endothelin1 (ET-1) mediated vasoconstriction. In 
three large randomized controlled trials called ‘Clazosentan to Overcome 
Neurological ischemia and infarction studies’ (CONSCIOUS), Clazosentan reduced 
angiographic vasospasm but failed to decrease mortality, morbidity and occurrence 
rate of cerebral infarction in SAH patients53 54. On the contrary, the calcium-channel 
blocker Nimodipine has been shown to relieve arterial narrowing and protect the 
brain from ischemia in various clinical trials 55. Voltage-dependent calcium channels 
were shown to play a role in the formation of vasoconstriction after SAH. Activation 
of calcium channel leads to a constriction of small cerebral arteries with diameters 
range from 100 to 200 μm56. Nimodipine blocks calcium mediated vasoconstriction 
and is beneficial in relieving middle cerebral artery spasms57, therefore restoring 
cerebral blood flow58. Additionally, Nimodipine was reported to have 
neuroprotective effects after SAH in both animal models and in human patients55 59. A 
meta-analysis based on 16 trials suggests that oral administration of 60 mg 
  
10 
Nimodipine every four hours is helpful for SAH patients55, thus application of 
Nimodipine received the highest possible level of evidence (A) in the American Stoke 
Association in SAH guidelines46. Maintenance of euvolemia with induction of 
hypertension was considered to be beneficial for maintaining cerebral perfusion 
pressure in patients with DCI42. A recent randomized clinical trial showed that 
induced hypertension in DCI patients may have serious adverse events60. Patients 
with symptomatic cerebral vasospasm should therefore be treated with cerebral 
angioplasty and/or intra-arterial application of vasodilators46. 
Since the disability rate among SAH patients is high, long term rehabilitation is 
important to regain daily living ability and labor capacity. Physical, occupational as 
well as psychological therapy should be initiated after being discharged from hospital.  
Over the past several decades, treatment for subarachnoid hemorrhage has been 
improved significantly mainly based on the early obliteration of aneurysms, improved 
intensive care management and the use of Nimodipine. Although there are several 
small non-randomized studies showed promising beneficial effects of Cilostazol, 
heparin, erythropoietin, eicosapentaenoic acid and methylpredinisolone, there are 
no newly emerging therapeutic measures61 and the clinical outcome of SAH patients 
is still disappointing.  
The failure of the CONSCIOUS trials suggests that the sole focus on treating delayed 
vasospasm might not be the right target. Actually, the intrinsic correlation between 
large arterial vasospasm and ischemic injury during DCI is somehow uncertain. 
Among all surviving SAH patients, only about 20-30% develop delayed ischemia 
accompanied with delayed vasospasm, while 21% of them suffer from delayed 
ischemia without the presence of delayed vasospasm62. On the contrary, early brain 
injury (EBI) is the leading cause of mortality after SAH63 64. Moreover, for those who 
survived from EBI, pathological mechanisms triggered by the initial damage continue 
affecting the course and outcome of SAH65-67.  Therefore within the past decade the 
focus of SAH research shifted towards EBI. However research regarding EBI after SAH 
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is still limited.  Thus, more research on EBI after SAH is needed to understand the 
pathophysiology and to identify new therapeutic targets68.  
1.2 Animal models 
There are various animal models being used in SAH research. In the intracisternal 
vein transection model, venous blood is released by cutting a vein at the skull base 
(cisterna pontis) that spills into the subarachnoid space69. In the extracranial 
intracranial arterial blood shunting model, the common carotid artery, abdominal 
aorta or femoral artery are shunted to the prechiasmatic cistern through a 
connecting catheter70. In the extravascular vessel and cerebral vessel puncture model, 
arterial blood spills into subarachnoid space by direct penetration with a needle 
through a burr hole70. 
  
Currently, the three mainly used animal models in SAH research are the direct 
intracisternal blood injection, endovascular puncture and clot placement. In the 
intracisternal blood injection model, single or double injection of autologous blood is 
performed71. Autologous arterial or venous blood is injected through a needle which 
is inserted into the prechiasmatic cistern, prepontine cistern, interpeduncular cistern, 
or most commonly cisterna magna. The injection volume ranges from 0.3 to 1.5 
ml/kg or 1.0 to 5.0 ml for rabbits,  0.1 to 0.5 ml for rats72 and 40 to 90 µl for mice73. 
For the double blood injection model, the interval time between the first and the 
second injection is 24 or 48 hours74. It mimics bleeding into subarachnoid space with 
a controllable blood volume and is fast, reproducible and easy to operate. Thus it was 
widely used for investigation of DCI and vasospasm in rats, rabbits and dogs75. 
However, it does not reproduce the pathophysiology of the process of artery rupture 
which happens in the clinical situation.  
Therefore an alternative approach for induction of SAH was developed in mice and 
rats: the endovascular puncture.70 This model was first described by Bederson et al64 
and Veelken et al76. A filament is inserted into external carotid artery and advanced 
up to the Circle of Willis in order to penetrate the arterial wall at the bifurcation site 
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of the middle cerebral artery. This imitation of the rupture of an aneurysm presents 
some of the most prominent clinical features that are also observed in SAH patients. 
The model exhibits rebleedings, a common complication after aneurysmal SAH35, and 
microarterial constrictions which occur in the stage of EBI77 78. Additionally, the 
adaptation to the mouse offers researchers the opportunity to use transgenic mice. 
Though microsurgery is relatively complicated to perform, using a standardized 
protocol set by Buhler et al.79 including ICP and CBF monitoring this model can be 
performed in a highly reproducible manner. Therefore the endovascular perforation 
model became very popular for the investigation of EBI after SAH. 
The craniotomy and clot placement SAH model is most commonly used in dogs and 
monkeys70. Since researchers speculate that a large bleeding volume might increase 
the risk of delayed cerebral vasospasm, maximum-sized artery blood clots were 
placed on exposed arteries after frontotemporal craniectomy. Thereby delayed 
cerebral vasospasms as well as neurological deficits were observed 7 days after clot 
placement80.  
Since the failure of the clinical Clazosentan trials, the focus of SAH pathophysiological 
studies shifted from DCI to EBI. Thus, the rodent model of endovascular puncture 
became the most common experimental SAH model.  
Though the endovascular puncture SAH model successfully replicates the natural 
course of SAH, by now there is no applicable animal model which could be used to 
study the pathogenesis of single factors after SAH. One aim of this thesis is therefore 
to develop a new animal model that allows researchers to study the effect of single 
or multiple pathogenic factors which influence the pathophysiological process after 
SAH. 
 
1.3 Pathophysiology 
1.3.1 Early brain injury 
The notion that early brain injury (EBI) after SAH is the leading cause of mortality in 
SAH patients was first suggested by Adams et al. in 198181. Later, Kusaka et al. 
defined EBI as an immediate injury to the entire brain after SAH82.  However for 
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several decades, studies of delayed brain injury and delayed cerebral vasospasm 
attracted most of the attention in SAH research. Only when Clazosentan, an 
endothelin A (ETA)-receptor antagonist which was shown to effectively decrease 
delayed vasospasm, did not improve clinical outcome after SAH, many researchers 
started to realize that the mechanism causing cerebral ischemia after SAH is 
multifactorial. It could well be that significant pathophysiological events independent 
of delayed vasospasm of large cerebral vessels occur soon after the bleeding and lead 
to secondary brain injury which result in poor clinical outcome83.  
1.3.1.1 Intracranial pressure 
Within one minute after the rupture of an intracranial aneurysm, extravasated blood 
bursts into the subarachnoid space, thereby causing a sudden increase of intracranial 
pressure (ICP). It usually reaches a peak as high as the mean systemic blood pressure. 
In most cases, ICP falls to a lower but still elevated plateau within several minutes84. 
In other cases e.g. when large hematomas form, severe brain edema or 
hydrocephalus develops and ICP remains high until these factors have been 
resolved85. Rapid rise of ICP may also induce immediate herniation and direct damage 
to brain tissue. In clinical data, an elevated ICP (> 20 mmHg) is associated with re-
bleedings and ischemic lesions within 72 hours and 7 days after SAH. An ICP value 
over 20 mmHg, however, shows a strong relationship with high mortality in patients86.  
1.3.1.2 Acute cerebral ischemia 
An acute and sudden increase of ICP results in significant decrease of cerebral 
perfusion pressure (CPP)87 and, hence, cerebral blood flow (CBF)64, which may lead to 
global cerebral ischemia. In experimental SAH, a global decrease of CBF was shown in 
rats 15 and 90 minutes after SAH88. In some cases CBF dropped to almost zero89. 
However, ICP increase is not the only cause for decreased cerebral perfusion after 
SAH. There is experimental evidence showing that cerebral perfusion shows a 
secondary reduction after CPP normalized64. These findings were later corroborated 
in SAH patients by Schubert et al.: twelve hours after the ictus, global cerebral 
ischemia still exist in SAH patients who are accompanied by only slight changes in ICP 
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and CPP.  This prolonged hypoperfusion independent of ICP and CPP is speculated to 
be associated with microvasculatory vasospasm90. Meanwhile, this initial impairment 
of cerebral perfusion correlates with the occurrence of DCI and clinical outcome in 
patients90 91, and is believed to be the leading cause of morbidity in SAH patients92.  
The initial CBF impairment activates a cascade of further pathophysiological events93. 
Apoptosis caused by ischemia was found in endothelial cells, neurons and astrocytes 
after SAH83 93 94.  Blood oxygen content decreases to about 60% immediately after 
SAH88. Hypoxia disturbs metabolic and ionic hemostasis, initiates inflammatory 
pathways and cerebral edema95. Microvasospasm in small superficial arteries and 
arterioles and decreased capillary density were found in patients three days after 
SAH77. Animal research also showed significant correlation of microvasospasm with 
decreased cerebral perfusion78. However, the mechanism behind formation of 
microvasospasm is not well understood.  
As one of the initial key factors occurring right after the rupture of an aneurysm is 
intracranial hypertension. The subsequent reduction in CBF may not only result in 
acute cerebral ischemia, but has also a far reaching influence on microcirculatory 
dysfunction afterwards96 97. Meanwhile, subarachnoid blood and its components may 
also play a crucial role in post-hemorrhagic cerebral ischemia. Currently, the 
mechanistic studies of ischemia after SAH were mostly performed with the blood 
injection model or perforation model with inconsistent experimental protocols. 
Despite the question to what extent these models resemble human SAH, the 
concurrently occurring mixture of different pathogenetic factors, such as increased 
ICP and blood accumulation, make it difficult to investigate the pathophysiological 
contribution of single factors in detail. Therefore we hypothesized that it is necessary 
to establish an animal model with blood accumulation similar to what is observed 
after MCA perforation but without ICP related hemodynamic changes. With such a 
model, it should be possible to look into the pathophysiological processes caused by 
single blood components or its lysates.   
  
15 
1.3.2 Inflammation 
Brain tissue damage secondary to global cerebral ischemia immediately activates 
inflammatory reactions. At the same time also blood coagulation and hemolysis 
products in the subarachnoid space initiate and exacerbate the inflammatory 
response. Inflammatory mediators such as intercelluar adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1, monocyte chemoattractant protein-1 and 
Eselectin are elevated in the CSF of patients after SAH98-100. As inflammatory cascades 
are being activated right after ictus, early inflammation has been speculated to play 
an important role in the pathophysiological process after SAH. Clinical studies show a 
correlation between increased inflammatory markers such as C-reactive protein (CRP) 
or Interleukin-6 (IL-6) and a poor clinical outcome of SAH patients101 102.  
There are several different inflammatory pathway involved in the inflammatory 
cascades after SAH. The mitogen-activated protein kinase (MAPK) pathway was found 
to aggravate blood brain barrier (BBB) breakdown and neuronal apoptosis through  
the downstream effector Matrix metallopeptidase 9 (MMP-9) in EBI after 
experimental SAH103 104.  Also myeloid differentiation factor-dependent pathways 
were demonstrated to be involved in neuroinflammation during EBI105. Furthermore, 
the nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NF-κB) signaling 
pathway also plays a crucial role in EBI106. Animal experiments aiming at suppressing 
these two pathways showed reliable neuroprotective effects and reduction of 
inflammation in different studies107-109. Cell surface receptors were also engaged in 
the exacerbation of the inflammatory response after SAH. Toll-like receptor 4 (TLR-4) 
was reported to be an independent predictor for poor neurological outcome in SAH 
patients110. A small scale phase II randomized controlled clinical trial with 136 
patients showed that an Interleukin-1 receptor antagonist, IL-1RA effectively reduced 
peripheral inflammation after SAH. However further investigation on clinical outcome 
are needed111.  
Significant up-regulation of endothelial adhesion molecules after SAH, e.g. ICAM-1, 
induce cellular interaction between circulating leukocytes and the cerebral 
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endothelium, a process speculated to be involved in the development of chronic 
vasospasm112 113. A recent study showed that an increased number of activated NK 
cells in CSF of SAH patients was associated with an increased risk of cerebral 
vasospasm and DCI 114. Additionally an in vivo experiment showed rolling and 
adhering leukocytes in the cerebral capillaries 60 minutes after SAH. These 
leukocytes decrease blood flow velocity and even plug vessels, thereby aggravating 
microcirculatory dysfunction after SAH115.  
Among all factors involved in the inflammatory response in the brain, microglia play a 
pivotal role116-118. Microglia are macrophage like cells which act as the first and main 
cellular immune defense mechanism in the central nervous system119. Usually, 
microglia rest in the brain and survey their surroundings for damage or potential 
threat. Once triggered by danger signals, resting microglia transform into an activated 
state. Activated microglia are classified into two categories: M1 microglia are 
considered to be the pro-inflammatory and release pro-inflammatory mediators such 
as interleukin (IL)-1β, IL-12, Tumor necrosis factor alpha and nitric oxide. M2 
microglia are considered to be anti-inflammatory and to be involved in tissue 
remodeling and repair120. In experimental SAH, microglia were shown to be involved 
in the induction of vasospasm in both the early and late phases121, causing delayed 
brain injury118 and contributing to neuronal cell death122. Promoting the polarization 
of microglia towards M2 phenotype by using erythropoietin could reduce neuronal 
necrosis and brain edema in EBI116. Thus, a modulation of intracranial immune cells 
could be a new target for relieving cortical inflammation after SAH.  
Although inflammatory reactions are considered to be essential for the 
pathophysiology of SAH, anti-inflammatory treatments with immune-modulating 
drugs such as nafamostat mesylate or cyclosporin A showed little success in clinical 
trials123 124.  The only exception was a trial on methylprednisolone which improved 
functional outcome in patients but did not reduce the incidence of symptomatic 
vasospasm125.   
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Since neuro-inflammation seems to be a complicated process including various 
players, more experimental as well as clinical studies are needed to shed more light 
onto this process in order to identify new therapeutic strategies.  
1.3.3 Delayed cerebral ischemia 
The first report about cerebral arterial constriction in SAH patients was in 1951126. By 
using arteriogram, arterial spasms were found in SAH patients in the later phase after 
SAH (23 days or earlier). Because of a strong association between delayed vasospasm 
and cerebral infarction, it was believed for decades that vasospasms, which occur in 
40% to 60% of patients between 3 to 14 days after SAH, are the single cause of DCI 
and poor outcome127 128. Various basic and clinical researchers focused on finding 
strategies which targeted delayed vasospasm. Endothelin (ET), by far the most 
powerful vasoconstrictor, was regarded as a key mediator for delayed vasospasm 
after SAH129 130. 
1.3.3.1 Endothelin receptors 
Endothelin (ET) is the most potent and persistent vasoconstrictor in the human 
cardiovascular system.  As its name implies, it is primarily produced by endothelial 
cells. There are three different isoforms of endothelin: ET-1, ET-2, ET-3 with a similar 
protein structure but distinct biological activities131. ET-1 is the strongest 
vasoconstrictor and also the most abundant isoform among them132. ET-1 was 
reported to be secreted by endothelial cells and vascular smooth muscle cells when 
superfused with oxyhemoglobin and cause arterial narrowing133. Clinical and 
experimental data suggest that after SAH, myofilaments in vascular smooth muscle 
cells become more sensitive to ET-1, which then leads to the development of cerebral 
vasospasm134 135. Other studies show that ET-1 concentration in the CSF was elevated 
in SAH patients136 and that it was released by monocytes isolated from CSF137. 
Nevertheless, there is conflicting data about the up-regulation of ET-1 in plasma or 
CSF of SAH patients137 138.  
ET-1 plays an essential role in the regulation of cardiovascular function through 
binding two G-protein coupled receptors, ETA and ETB.  ETA receptors are 
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predominantly expressed in vascular smooth muscle cells and are responsible for 
vascular activity and function, especially vasoconstriction139. ETB receptors internalize 
ET-1140 and facilitate the generation of the vasodilator nitric oxide (NO) 141. ETA  
receptors have a higher affinity to ET-1 and conducts ET-1 mediated 
vasoconstriction142. As more and more studies reported an elevated level of ET-1 
after SAH, ETA receptor antagonists emerged as a promising methods for the 
treatment of cerebral vasospasm after SAH143.  
Clazosentan is an ETA  receptor antagonist specifically designed for parenteral 
application in patients with SAH144. It was shown to alleviate angiographic vasospasm 
and prevent CBF reduction in animal SAH experiments145 146. However, Clazosentan 
failed to improve functional outcome and survival rate in clinical trials, despite an 
alleviation of delayed cerebral vasospasm53 54. In contrast it was associated with 
worse clinical outcomes because it was causing side effects like pulmonary edema, 
hypotension and anemia147 148. The failure of the Clazosentan trials revealed that DCI 
is actually a multifactorial pathophysiological process: beside vasospasm, 
neuroinflammation, microthrombosis, cortical spreading depolarization and EBI are 
also involved in the pathogenesis of DCI143 149 150. The failure of the Clazosentan 
clinical trials also indicated that poor outcome is caused by mechanisms other than 
large artery spasms.  This moved the whole SAH research community into a new era 
of re-understanding and re-exploring the relevant mechanisms responsible for 
delayed cerebral ischemia.  
1.3.4 Dysfunction of the cerebral microcirculation 
Microcirculatory dysfunction after experimental SAH was first reported by Herz et al. 
in the early 1970ies. After topical application of blood onto pial vessels Herz and 
coworkers observed vasoconstriction and disturbed blood flow in cerebral pial 
vessels of guinea pigs151. In various SAH animal experiments, microcirculatory 
changes including altered vasoreactivity, increased inflammation, BBB disruption, 
microvasospasm, increased microthrombosis, and pathological inversion of 
neurovascular coupling were also reported78 82 152-155. The mechanisms underlying 
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microcirculatory dysfunction are complex and still remain to be explored. One aim of 
this thesis was to study the mechanisms behind microvasospasm and identify new 
therapeutic targets to relieve posthemorrhagic ischemia in EBI after SAH.  
1.3.5 Microthrombosis 
Clinical studies show a correlation between the activation of the coagulation cascade 
and the development of DCI156 157. Patients who died from DCI have more 
microthrombi in the infarcted brain regions158. Thus microthrombosis is regarded as 
one of the key mechanisms for the development of DCI149. It also contributes to the 
microcirculatory failure in EBI78. 
Cerebral microthrombi usually consist of aggregated platelets and fibrin and are 
sometimes mixed with leukocytes158.  After SAH, decreased cerebral blood flow 
velocity can increase blood viscosity and thereby lead to intravascular 
microthrombosis and capillary obstruction159 Furthermore, decreased intravascular 
NO levels can also promote platelet aggregation and cause microthrombi 
formation160. Sehba et al. showed a time line determined by histological staining for 
the formation of micro thrombi in rats after SAH. 10 minutes as well as 24 hours after 
SAH, platelet aggregates reached a peak, but no immunoreactive aggregates were 
observed 48 hours after the bleeding161. An in vivo study from our laboratory showed 
30% constricted arterioles with microthrombi occlusion and the degree of 
vasoconstriction correlating with the frequency of microthrombosis78. Consistent 
results were found in SAH patients where platelet aggregation may promote 
endothelial damage162. An increased number of microthrombi is associated with 
delayed cerebral ischemia158.  
The effect of common antiplatelet drugs such as acetylsalicylic acid, dipyridamole or 
ticlopidine after SAH is unclear. Apart from the increased risk of hemorrhagic 
complications, they show a trend to improve outcome by reducing secondary 
ischemia, but the results were not statistically significant thus to date antiplatelet 
drugs cannot be recommended for the treatment of secondary ischemia or poor 
outcome after SAH163.  
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1.3.6 Mircovasospasm 
Bederson et al. found acute vasoconstriction in the internal carotid artery and the 
anterior cerebral artery after experimental SAH in rats164. Interestingly, 
vasoconstriction occurs independent of ICP and CPP but is associated with decreased 
CBF, larger hemorrhage size, persistently elevated extracellular glutamate levels and 
poor general outcome. In this study the authors speculated that acute 
vasoconstriction might contribute to ischemic brain injury after SAH164. In SAH 
patients, microvasospasm of pial vessels was first observed by Uhl et al. who 
reported that 50% of superficial arteries showed vasospasm and reduced capillary 
density77. Increased microvascular contractility is believed to increase the 
susceptibility to ischemia and to worsen clinical outcome77 165.  
In theory, microvasospasm is a general term describing vasoconstriction that happens 
in small vessels. The importance of microvasospasm is mainly based on the functional 
fact that small vessels including superficial cerebral arteries, penetrating arterioles 
and parenchymal arterioles are resistance arteries. By altering vessel diameter, they 
provide a major component for the regulation of blood flow97 166. It is easy to assume 
that constriction of resistance arteries will lead to a drastic change of blood flow on 
the parenchymal level.  
This has been shown by previous work in our lab. Microvasospasm in a mouse SAH 
model seem to be restricted to pial vessels, 20-40% of pial arterioles constriction 
were found as early as three hours after hemorrhage and lasted for up to 72 hours78. 
A 20% reduction of superficial arterioles diameter is associated with a 60% reduction 
of flow, which indicates even small spasms result in a parenchymal perfusion deficit.  
Since after SAH, superficial microvasospasms are related with changes of the 
parenchymal perfusion volume, the disintegration of superficial microvasospasm 
could probably ameliorate ischemia and improve outcome. Therefore one of the aims 
of this thesis was to explore the pathomechanisms behind microvasospasm after SAH. 
As described before, endothelin receptor antagonist Clazosentan could relieve large 
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artery spasm by competitively binding to the ETA receptor. We speculated that the 
mechanism behind large artery spasm and microvasospasm could probably be the 
same. Thus we aimed to conduct experiments investigating whether Clazosentan 
could relieve microvasospasm through the inhibition of ETA receptors. 
1.3.7 Hemolysis 
Hemolysis describes the rupture of erythrocytes and the release of its contents, 
mainly hemoglobin (Hb). Two hours after SAH, Barrows et al. found that the 
hemolysis product hemoglobin (Hb) was present in patients’ CSF 167. In animal 
experiments Peterson et al. showed that the development of vasospasm depends on 
hemolysis after SAH in dogs168. In isolated arteries, hemolyzed blood induced 
significant vasoconstriction via an increase of intracellular Ca2+ concentration169. 
Widespread cortical infarction can be induced by superfusion of the subarachnoid 
space with Hb combined with either high potassium or low glucose solution94. 
Hemolysis products including Hb, bilirubin oxidation products, free heme or iron are 
shown to be responsible for large cerebral vasospasms after SAH in different 
stuides170-173. 
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Figure 3 
In the systemic circulation the CD163-haptoglobin-hemoglobin (CD163-Hp-Hb) 
scavenger system is the primary pathway for Hb clearance. The system exists also in 
the central nerves system (CNS), but its capacity is much lower-than in blood174. 
Extracellular Hb in the circulation will be captured by haptoglobin (Hp) and engulfed 
by macrophages or monocytes through the receptor CD163175. In the brain, 
perivascular and meningeal macrophages express  CD163 and act as Hb scavengers. 
By checking Hp and free Hb level in the CSF of patients, it was demonstrated that the 
CD163-Hp scavenger system is saturated several days after SAH. This indicates an 
incapability of the subarachnoid space to handle significant hemolysis after SAH174.  
 
Excessive free Hb due to hemolysis causes damage to cells and tissue mainly through 
three mechanisms. First, Hb as a small molecule can easily get access to the 
intercellular space such as subendothelial and perivascular spaces176. There it can 
directly generate adverse effects. Second, Hb reacts with reactive oxygen species 
such as hydrogen peroxide or lipid peroxides and generates superoxides and free 
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radicals. End products of the oxidization process trigger cellular injury and may be 
related to delayed vasospasm177. Scavenging of superoxides and free radicals 
ameliorates vasospasm after experimental SAH178 179. Oxidation of hemoglobin 
generates methemoglobin, a product found in the subarachnoid space after SAH in 
animals180 and promoting TLR4 mediated neuroinflammation in vitro181. 
Third, methemoglobin is an unstable complex so heme is rapidly released and 
interferes with molecular signaling pathways by binding with certain receptors, 
transcription factors or enzymes182 183. Free heme will conduct oxidation of 
membrane lipids and lipoproteins therefore inducing cellular dysfunction and cell 
death184. In physiological circumstances, hemopexin binds and transits heme into 
macrophages where the heme oxygenase-1 (HO-1) breaks down heme into billiverdin, 
carbon monoxide and iron185. Unlike biliverdin and carbon monoxide which have anti-
inflammatory effects186 187, free heme and iron have a direct cytotoxic effect to cells 
and are able to activate the innate immune response thereby inducing 
inflammation188.  
The CD91-hemopexin scavenger system is the second line for Hb clearance; a small 
amount of hemopexin was found in the cerebral vascular system, expressed in the 
basement membrane and connective tissues. Though evidence shows that the CD91-
HPX system is activated in the brain after SAH, due to low expression of hemopexin, 
the heme-binding capacity in the brain does not seem to be high enough to process a 
heme overload after hemolysis as CSF sampling from SAH patients shows that the 
heme-hemopexin uptake is saturated already early after SAH189.  
Ferritin is an intracellular protein that binds iron and stores it intracellularly in a non-
toxic form and is highly expressed in cerebral arteries after SAH in animal models190 
and in CSF samples of patients191. HO-1 concentration in the CSF was shown to be an 
effective predictor for the clinical outcome of SAH patients192. The inhibition of HO-1 
worsens and prolongs the spasm of the basilar artery in rats after SAH193. 
Because of its detrimental effects, the binding of free iron with chelators seems to be 
a promising therapeutic approach in diseases which are associated with hemolysis. In 
terms of free iron inhibition, various iron chelators were tested in experimental SAH 
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animal models. 2,2'-dipyridyl was found to reduce delayed vasospasm of the middle 
cerebral artery and basilar artery in monkeys and rabbits after SAH194 195. Deferiprone 
was shown to attenuate basilar artery vasospasm in rabbits196.  
Another potent iron chelator is deferoxamine (DFO). DFO is clinical commonly used 
and was shown to prevent post-hemorrhagic injury by neutralizing iron toxicity and 
inhibiting oxidative stress, phagocytosis, apoptosis and inflammation after 
intracerebral hemorrhage197 198. As shown by a meta-analysis, DFO is neuroprotective 
and improves neurobehavioral outcomes after intracerebral hemorrhage199. 
Interestingly, attenuation of large artery vasospasm after DFO application was found 
in the double injection rat SAH model200 but not in prechiasmatic cistern injection 
mouse SAH model201. A vasospasm independent neuroprotective effect was seen in 
different studies173 200-203. The possible modes of action include inhibition of cathepsin 
B/D release, increase of HO-1 and hypoxia-inducible factor-1 expression, reduction of 
BBB impairment and neuronal cell death and thereby improvement of neurological 
function173 200-203.   
Taken together, hemolysis products in the subarachnoid space might play a 
substantial role in the pathophysiological processes after SAH. Most previous studies 
investigating the role of hemolysis products after SAH focused on DCI and only 
recently the importance of iron chelation in EBI attracted more attention. One aim of 
this thesis was therefore to investigate the role of hemolysis products in the context 
of microcirculatory dysfunction after SAH. We aimed to test whether DFO applied 
directly to the subarachnoid space prevents the formation of microvasospasm by 
neutralizing iron as soon as it is released by hemolysis.  
To sum up, we first aimed at investigating whether ETA receptor antagonist 
Clazosentan has an effect on early microvasospasms after SAH, thus checking if the 
ETA receptor is involved in the development of acute microcirculatory dysfunction 
after SAH.  The second aim of the study was to describe the distribution pattern of 
extravasated blood in the MCA perforation model in order to identify its causative 
relationship with microcirculatory dysfunction. Our hypothesis was that the blood 
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distribution in the subarachnoid space will have an impact on the cerebral circulation 
by releasing detrimental hemolysis products. The third aim of the study was to 
explore the potential effect of free iron in the formation of microvasospasms by using 
the iron chelator DFO. In order to further study the role of hemolysis products in 
microcirculatory dysfunction after SAH, we also aimed at establishing a novel in vivo 
animal model with a similar blood distribution pattern as in SAH but which is 
unaffected by initial cerebral perfusion deficits.  
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2. Methods and Materials 
2.1 Materials 
2.1.1 Equipment 
 
Axio Imager M2 Microscope Co. Zeiss (Germany) 
Cryostat NX70                                       Co. Thermo Scientific (USA) 
DC Temperature Control System         Co. FHC (USA) 
Dental Drill                                                    Co. Rewatronik (Germany) 
Dental Drill Tip (GD041R, 6mm/ISO, 
2.35X70mm) 
Co. B-Braun (Germany) 
Dumont Forceps (11253-20) Co. Fine Scientific Tools (Switzerland) 
Dumont Laminectomy Forceps       
(11223-20) 
Co. Fine Scientific Tools (Switzerland) 
Extra Fine Bonn Scissor (14084-08) Co. Fine Scientific Tools (Switzerland) 
Fume Hood                                                         Co. Wesemann (Germany) 
Hartman Hemostat (13003-10) Co. Fine Scientific Tools (Switzerland) 
Incubator Co. Memmert (Germany) 
Intracranial Pressure Express                          Co. Codman, J&J (UK) 
Intubation tube                                                  Custom made from a 20G venous catheter 
LED light source (KL2500)      Co. Leica (Germany) 
Leica M80 Stereomicroscope                           Co. Leica (Germany) 
Li:Ti Laser, Chameleon                                                             Co. Coherent (Scotland) 
MediHEAT Heater                                               Co.Peco Services (UK)                                                     
Microcapnograph 340                                        Co. Hugo Sachs (Germany) 
MicroSyringe Pump Controller                  Co. World Precision Instruments (USA) 
Micro Serrefine (18055-04) Co. Fine Science Tools (Switzerland) 
Micro-Serrefine Clamp Applying Forcep 
(18057-14) 
Co. Fine Science Tools (Switzerland) 
Minivent 845                      Co. Hugo Sachs (Germany) 
  
27 
Nose Clamp                                   Co. David Kopf Instrument (USA) 
Oslen-Hegar Needle Holder (12002-12) Co. Fine Science Tools (Switzerland) 
Oxygen Sensor, Oxydig                          Co. Draegerwerk (Germany) 
Perfusion Machine                  Co. Leica Biosystems Richmond (Germany) 
PeriFlux system 5000            Co. Perimed AB (Sweden) 
PhysioSuite  PS-03    Co. Kent Scientific (USA) 
Powerlab 8/35       Co. AD Instruments (Australia) 
RAPIDLab 348 Blood Gas Analyzer                     Co. Siemens (Germany) 
Stereotactic Injection Platform                Co. Föhr Medical Instruments (Germany) 
Synergy Water Purification System Co. Sigma-Aldrich (USA) 
Syringe Pump (SP101IZ)                                                        Co. World Precision Instruments (USA) 
Two Photon Microscope LSM 7 MP                    Co. Carl Zeiss (Germany) 
Vannas Spring Scissors (15000-08)   Co. Fine Science Tools (Switzerland)  
Venous Catheter (20G)                                        Co. BD Biosciences (USA) 
Vibratome (Leica VT 1200s)   Co. Leica (Germany) 
X-cite 120 Fluorescence Illuminator     Co. Lumen Dynamics (USA) 
 
2.1.2 Software 
 
ImageJ 2  National Institute of Health (USA) 
Imaris      Co. Bitplane AG (Switzerland) 
LabChart 8 Reader                                                Co. ADInstruments (Australia) 
SigmaPlot 13.0                                                         Co. Systat (USA) 
ZEN 2010                                                                Co. Carl Zeiss (Germany) 
 
2.1.3 Consumables 
 
Accelerator Insta-set                               Co. Drechseln & Mehr (Germany) 
Carboxylatzement Fluid                                           Co. Dr. Speier (Germany) 
Carboxylatzement Powder                                          Co. Dr. Speier (Germany) 
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Cotton Swab                                                                Co. Nobamed Paul Danz (Germany) 
Coverslips   Co. Warner Instruments (USA)                      
Cyano Veneer                                                         Co. Hager & Werken (Germany) 
Cyano Veneer Powder                                            Co. Hager & Werken (Germany) 
Cyanoacrylate Maxi-Cure                                    Co. Drechseln & Mehr (Germany) 
Dental needle (30G)                                                          Co. Septodont (Germany) 
Eukitt Quick-hardening Mounting Medium Co. O.Kindler (Germany) 
Eye and nose ointment                           Co. Bayer Vital (Germany) 
Fine bore polythene tubing: 0.38mm (ID), 
1.09mm (OD)                          
Co. Smiths Medical ASD (UK) 
Gauze (7.5 x 7.5 cm) Co. Lohmann & Rauscher(Germany) 
Injekt-F Syringe (1ml) Co. BD Biosciences (USA) 
Laser Doppler Probe Microtip Co. Perimed AB (Sweden)                                         
M-1 Embedding Matrix                                                 Co. Thermo Scientific (USA)                    
Mounting Medium for Fluorescence Co. Vector Laboratories (USA)                                                                 
Nail polish (transparent) Co. Dm Drogerie Markt (Germany) 
Needle (30G/0.3mm)                                                                Co. B-Braun (Germany) 
Polytetrafluorethylen hose: 0.2mm (ID),  
0.4mm (OD) 
Co. Bohlender (Germany)                                        
Prolene Suture (5-0)                                                            Co. Ethicon (Germany) 
Scalpel (No.11)     Co. Feather (Japan) 
SERAFIT Suture (6-0)                                                 Co. Serag Wiessner (Germany) 
Silk Braided Suture (7-0)                                               Co. Pearsalls Limited (UK)  
Sugi Sponge Points                                                Co. Kettenbach (Germany) 
Superfrost Plus Microscope Slides                          Co. Thermo Scientific (USA)                    
Surflo Winged Infusion Set                            Co. Terumo Medical Corporation  
(Belgium)  
Vasco Nitril Blue Glove (S) Co. B-Braun (Germany) 
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2.1.4 Chemicals 
 
ABC kit (Vectastain)                                         Co. Vector Laboratories (USA) 
Acetone Co. Applichem (Germany) 
Agarose Co. VWR (Germany) 
Antipamezol (Alzane 5mg/ml)                          Co. Zoetis (USA) 
Aqua ad injectabillia                                                  Co. Fresenius Kabi (Germany) 
Artificial Cerebrospinal Fluid                                                                           Co. Ecocyte bioscience (USA) 
Avidin/Biotin Blocking Kit                          Co. Vector laboratories (USA) 
Bovine Serum Albumin                                Co. Sigma-Aldrich (USA) 
Buprenorphine (Buprenovet 0.3mg/ml)                Co. Bayer (Germany) 
Carprofen (Rimadyl 50mg/ml)                                Co. Zoetis (USA) 
Clazosentan  Co. Actelion (Switzerland) 
3,3’-Diaminobenzidine (DAB) kit                                                              Co. Vector laboratories (USA) 
Deferoxamine (Desferal 100mg/ml)           Co. Novartis (Germany) 
Dextran Tetramethylrhodamine(TMRM), 
Lysine fixable (average 70,000 MW)               
Co. Sigma-Aldrich (USA) 
Ethanol (EMSURE, ≥99.8%)                          Co. Sigma-Aldrich (USA) 
Ethylene glycol                                                       Co. Sigma-Aldrich (USA) 
Fentanyl (Fentadon 50mg/ml)                                 Co. Albrecht (Germany) 
FITC (Tomato) Lectin    Co. Vector Laboratories (USA) 
Flumazenil   Co. Hexal (Germany) 
Fluorescein isothiocyanate-dextran 
(average 70,000 MW)               
Co. Sigma-Aldrich (USA)                                          
Glycerol    Co. Sigma-Aldrich (USA)                                                   
Hematoxylin Co. Sigma-Aldrich (USA) 
Heparin-Natrium (25,000 I.E./5ml)                                                                     Co. B-Braun (Germany)
Hydrogen Chloride Co. Sigma-Aldrich (USA) 
Hydrogen Peroxide (30%)                                  Co. Sigma-Aldrich (USA) 
Isoflurane Isp-Vet                                      Co. Chanelle (Ireland) 
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Isopentane Co. Sigma-Aldrich (USA) 
Lidocaine (2%HCl)                                      Co. B.Braun (Germany) 
Medetomidine             Co. Zoetis (USA) 
Midazolam   Co. B-Braun (Germany) 
NaCl isotonic solution 0.9%                        Co. Fresenius Kabi (Germany) 
Naloxone Co. Inresa Arzneimittel (Germany) 
Paraformaldehyde (4% PFA)                                Co. Morphisto (Germany) 
Pepsin      Co. Dako (Germany) 
Phosphate buffer saline (PBS, 10x) Co. Klinikum Apotheke (Germany) 
Sucrose    Co. Sigma-Aldrich (USA) 
Tween 20                                                                   Co. Carl Roth (Germany) 
 
2.1.5 Antibodies 
 
Anti-Ly76 antibody TER119 (ab91113)                         Co. Abcam (UK) 
Anti-collagen type IV (Rabbit) antibody (600-
401-106.0) 
Co. Rockland (USA) 
Biotinylated goat anti-rabbit IgG antibody  
(BA-1000)      
Co. Vector Laboratories (USA) 
Biotin-SP Affinipure F (ab )´2 Fragment  
mouse anti-rat IgG (H+L) (212-066-168) 
Co. Jackson Immunoresearch (USA) 
Purified rat anti mouse CD45 (550539)                         Co. BD biosciences (USA) 
 
2.1.6 Buffers and solutions 
 
4% Agarose: 
8g           Agarose 
200ml  PBS (1x) 
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0.25% PBS-Tween: 
2.5ml           Tween20  
1L    PBS (1x) 
 
1% Hydrogen peroxide (H2O2): 
1ml          30% H2O2 
100ml PBS (1x) 
                                                                            
PBS, 1x: 
100ml  PBS (10x) 
900ml  Millipore water 
 
Pepsin solution: 
2mg Pepsin 
2ml HCl (0.2N) 
 
Blocking solution for brain tissue sections:  
0.2g    Bovine serum albumin 
10 ml PBS (1x) 
 
15% Sucrose solution for cryoprotection: 
37.5g  Sucrose 
250ml  PBS (1x) 
 
30% Sucrose solution for cryoprotection: 
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75g Sucrose 
250ml  PBS (1x) 
 
Cryoprotection solution: 
250ml Glycerin 
250ml   Ethylenglycol 
500ml PBS (1x) 
 
2.2 Methods 
2.2.1 Randomization and blinding 
For each set of experiment, animals were randomly assigned to surgical groups. 
Drugs and blood or artificial cerebral spinal fluid (aCSF) were prepared by an assistant 
researcher in advance and randomly marked to blind the researcher towards the 
respective treatment.  
Data collection and analysis were performed by the researcher blinded with respect 
to the treatment group. 
2.2.2 Animals 
All procedures on animal were approved by the Government of Upper Bavaria 
(protocol number 136-11 and 209-16) and are reported in accordance with the 
ARRIVE (Animal Research: Reporting of in Vivo Experiments) guidelines. All efforts 
were made to minimize animal suffering and to reduce the number of animals.  
All experiments were conducted on male C57BL/6N mice obtained from Charles River 
(Sulzfeld, Germany). Mice were group housed in individually ventilated cages under a 
twelve hour light cycle with access to food pellets and water.  
2.2.3 Filament perforation SAH model 
2.2.3.1 Anesthesia 
Mice were put into a darkened induction chamber with increasing isoflurane 
concentration until they lost consciousness then intraperitoneally injected with 0.05 
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mg/kg Fentanyl, 0.5 mg/kg Medetomidine and 5 mg/kg Midazolam via a 27-gauge BD 
syringe. Surgical anesthesia was confirmed by the loss of hind paw reflex. For 
sustained anesthesia, one third of the initial dose was injected regularly.  
Anesthetized mice were intubated with a custom tube made from a 20G venous 
catheter and put on a heating pad for maintenance of the body temperature. 
Controlled mechanical ventilation with oxygen supplemented room air was 
performed with a mechanical ventilator (Minivent). Ventilation volume as well as 
respiratory frequency was adjusted according to end tidal partial pressure of carbon 
dioxide (pCO2), which was measured with a microcapnograph (Microcapnograph 340). 
A pulse oximeter (PhysioSuite PS-03) was clipped at the right hind paw to monitor 
heart rate and peripheral oxygen saturation during anesthesia.  
All physiological parameters were recorded by Powerlab and displayed, stored and 
analyzed using LabChart software.   
2.2.3.2 SAH model 
SAH induction was performed as previously described204 by endovascular perforation 
of the Circle of Willis. As illustrated in Figure 4, an intracranial pressure (ICP) probe 
was first implanted through a burr hole between skull and dura mater. A laser 
Doppler probe for continuous measurement of cerebral blood flow (CBF) was fixed 
with glue (Cyanoacrylate Maxi-Cure) on the ipsilateral temporal bone above the 
territory of the middle cerebral artery. Afterwards, the mouse was placed in a supine 
position.   
  
34 
 
Figure 4: Schematic of intravascular perforation SAH model. The surgical site is located at the 
left side of the neck. Common carotid artery (CCA) and external carotid artery (ECA) are 
exposed. A blunt-ended filament (5-0 prolene, 12mm) is inserted through the ECA, advanced 
up to internal carotid artery (ICA) and penetrating the vessel wall at the Circle of Willis close 
to the middle cerebral artery (MCA). ACA = anterior cerebral artery, BA = basilar artery, PCA 
= posterior cerebral artery, SCA = superior cerebellar artery. (adapted from Schuller et al 204.)      
Common carotid arteries were exposed at the neck by a midline skin incision. A 
filament with a blunt end was inserted into the external carotid artery and advanced 
up to the bifurcation of the middle cerebral artery at the Circle of Willis. A sharp 
increase of ICP indicated the rupture of the arterial wall. The filament was quickly 
withdrawn in order to allow blood to freely flow into the subarachnoid space. The 
filament was removed and the external carotid artery as well as the skin wound was 
sutured. 0.1 mg/kg Buprenorphine was injected for postoperative analgesia. The 
physiologic parameters were continuously monitored for another 20 minutes. For 
termination of anesthesia 2.5 mg/kg Atipamezol, 0.5 mg/kg Flumazenil and 1.2 mg/kg 
Naloxone were injected subcutaneously. 
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2.2.4 Cisterna magna injection (CMI) model 
2.2.4.1 Anesthesia 
Mice were first put into a darkened chamber with increasing isoflurane concentration 
until loss of consciousness and then anesthetic agents (0.05 mg/kg Fentanyl, 0.5 
mg/kg Medetomidine and 5 mg/kg Midazolam) were injected intraperitoneally. Hind 
paw withdrawal reflex was checked regularly. Anesthesia during surgery was 
maintained by intraperitoneal injections of one third of the initial dose of anesthetics. 
Carprofen (4 mg/kg) was injected subcutaneously for analgesia. Buprenorphine 0.1 
mg/kg was injected 30 minutes before wake up of the mice for acute postoperative 
analgesia.  
Mice were put on a heating pad to maintain normal body temperature and ventilated 
with oxygenized (30%) room air. A pulse oximeter was clipped on the right hind paw 
to monitor heart rate and peripheral oxygen saturation during anesthesia. A syringe 
flushed with 0.1 % heparin in saline was used to withdraw 0.1 ml autologous blood 
from the left femoral vein. An intraperitoneal injection of 0.15ml saline reconstituted 
the volume loss. Blood was stored on ice for no longer than 15 minutes.  The wound 
was sutured, mice were turned over and a laser Doppler probe was fixed on the right 
temporal bone.  
2.2.4.2 Cisterna magna injection (CMI) 
CMI was redesigned and performed based on a previously described blood injection 
SAH mouse model205.  
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Figure 5 : Simplified sketch of cisterna magna injection edited from Light et al206. The cisterna 
magna is one of the subarachnoid cisterns. It located between the cerebellum and the dorsal 
surface of the medulla and covered by the dura mater and atlanto-occipital membrane. By 
widening the space between the end of occipital bone and atlas, it can be exposed for 
injection.  
A sketch of the injection point is shown in Figure 5. Briefly, mice were placed in a 
prone position and the head was fixed with ear bars. A midline incision was made and 
the occipital muscles were dissected bluntly to expose the posterior atlanto-occipital 
membrane. The head was then bent down rostral. A 30G dental needle fixed on a 
stereotactic micromanipulator was used to puncture the atlanto-occipital membrane. 
0.1 ml autologous blood was warmed by hand and mixed with 10 μl FITC dextran, or 
0.1 ml previously prepared aCSF (pH 7.4) was mixed with 10 μl FITC dextran. 22 μl of 
blood or aCSF was injected using a micro-syringe pump controller with an injection 
speed of 6.7 μl/min. After injection, the mouse was continuously monitored for five 
minutes. Then the wound was sutured and anesthesia was antagonized as described 
above. 
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2.2.5 Two-photon microscopy 
Anesthetized mice were fixed in a nose clamp and placed under the 2PM. FITC 
dextran (0.5% in saline) was injected through the femoral catheter to stain blood 
plasma. The excitation wavelength for FITC dextran and TMRM dextran was 830nm. 
500-550 nm and 565-610 nm band pass filter was used to detect the fluorescence of 
FITC dextran and TMRM dextran.  
Intravital microscopy is illustrated in Figure6 B and C. Four or two regions of interest 
(ROI) as well as thinned skull area with at least one artery with several branches or a 
vein were focused under the 2PM. By recording a pile of images at different focal 
planes with one μm step distance, Z-stacks of each ROI were obtained. Detailed 
information will be described in each experiment protocol. 
Blood flow velocity was recorded by performing line scans along pial arterioles, veins 
and capillaries207. Each vessel was scanned repetitively for 1000 times with maximum 
speed over a length of 20-50 μm to detect travelling erythrocyte.  
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Figure 6: (A) Sketch of an open cranial window (black frame) and a thinned skull window 
(green outline) on the left parietal cortex (Edited from discoverlife.org). (B) Four or two 
randomly chosen ROI within the cranial window were investigated by 2PM. 
2.2.5.1 Cranial window preparation 
2.2.5.1.1 Thinned skull window 
A thinned-skull window preparation was conducted as previously described208. Mice 
were anesthetized and fixed in a nose clamp. After topic application of lidocaine (2% 
HCl), the skull bone was thinned by using a dental drill (Dental Drill Tip GD041R). 
Topic saline was constantly applied to absorb the heat generated from the drilling 
process and thereby protecting the brain surface from overheating. The location of 
the thinned skull window is depicted in Figure 6 A.  
2.2.5.1.2 Open cranial window 
An open cranial window preparation was conducted as previously described209.  Mice 
were anesthetized and fixed in a nose clamp. After topic application of lidocaine, a 3 
x 3 mm sized window was drilled over the right hemisphere under constant cooling 
with topical saline. The dura mater was kept intact during drilling. After careful 
removal of the bone flap, the exposed dura mater was kept wet. The location of the 
open cranial window is depicted in Figure 6 A. 
2.2.6 Tissue harvesting 
At the end of imaging, an arterial blood sample from the femoral artery catheter was 
collected with a glass capillary for blood gas analysis.  
Transcardial perfusion was performed under a fume hood in deep anesthesia. The 
cardiovascular system was first perfused with saline for five minutes and then with 4% 
PFA for ten minutes. Perfusion pressure was kept at 150 mmHg throughout the 
process. 
Subsequently, brains were collected and post-fixed in 4% PFA overnight at 4°C. Brains 
were washed in PBS, embedded in 4% agarose and cut into 50 μm thick sections 
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using a vibratome (Leica VT 1200s). Sections were collected in a cryoprotectant 
solution and then analyzed or stored at -20°C for long-term preservation.  
In the DFO experiment, brains were collected and post-fixed in 4% PFA overnight at 
4°C. After washing in PBS, brains were cryoprotected by saturation in 30% sucrose 
solution. Then brains were rapidly frozen in -80°C isopentane and cut into 20μm thick 
sections at a cryostat. Sections were stored at -20°C until further processing.   
2.2.7 Experimental protocols 
 
Figure 7:  The intravital microscopy experimental groups and protocols used in this thesis. 
The dark blue dotted lines indicate infusion of drug/blood or vehicle/aCSF. (A) Clazosentan 
experiment. (B) CMI experiment. (C) DFO experiment.  
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2.2.7.1 Clazosentan 
The experimental protocol for the Clazosentan experiments is illustrated in Figure 7 A.  
Briefly, MCA perforation SAH was induced at time point zero. After monitoring of 
physiologic parameters for 20 minutes, mice were allowed to wake up for two hours 
and then re-anesthetized. An arterial catheter was inserted into the femoral artery to 
monitor blood pressure. A venous catheter at the same site was prepared for drug 
application. One bolus of Clazosentan (10 mg/kg) or vehicle was given three hours 
and 20 minutes after the induction of SAH. Afterwards a continuous administration 
via a femoral vein catheter was maintained by a syringe pump with a speed of 0.2 
ml/h for 30 minutes. A cranial window was prepared and cerebral vessels were 
imaged under the 2PM. Either Clazosentan or saline was continuously infused for 30 
minutes. During one hour of treatment and post treatment, two ROIs, each 1x2 tile 
scan with 0.7 x zoom were scanned. Therefore the size of each ROI was 607 x 1215 
μm. Imaging was performed at a depth of 150 to 500 μm every ten minutes. At the 
end of imaging a blood sample was drawn from the femoral artery catheter for blood 
gas analysis and mice were sacrificed by perfusion fixation. 
2.2.7.2 Blood and aCSF injection 
The experimental protocol for the injection of blood and aCSF into the cisterna 
magna is illustrated in Figure 7 B. Briefly, cisterna magna injection of blood or aCSF 
was done at time point 0. After monitoring the cerebral perfusion for five minutes, 
mice were allowed to wake up for two hours. Before re-anesthetizing the animal the 
neuroscore (Table 1) was assessed. A catheter was inserted into the femoral artery to 
monitor blood pressure. A cranial window was drilled and mice were put under the 
2PM for in vivo microscopy (IVM). Two ROls with a size of 425 x 425 μm were imaged 
at a depth of 150 to 500 μm. At the end of imaging a blood sample was drawn and 
mice were perfused for histological examination. 
2.2.7.3 Deferoxamine 
The surgical protocol of DFO experiments is illustrated in Figure 7 C. Briefly, a thinned 
skull window was drilled followed by a randomized intravenous infusion of DFO (200 
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mg/kg) or vehicle (aqua ad injectabillia). DFO (200 mg/kg) was injected approximately 
30 minutes before SAH via the femoral vein by using a vein injection syringe, which 
was composed of a sharp-tipped polytetrafluorethylen hose. At the same time TMRM 
dextran (0.5%in saline) was injected to label extravasated blood plasma. MCA 
perforation SAH was induced at time point zero. After 20 minutes monitoring of 
physiologic parameters, mice were woken up for about two and a half hours. Then 
they were anesthetized and a catheter was inserted into the femoral artery to 
continuously monitor blood pressure. Mice were put under the 2PM for IVM. During 
imaging, four ROI with a size of 607 x 607 μm were obtained with a 0.7 x zoom. The 
depth of the scan was 150 to 400 μm. At the end of imaging, a blood sample was 
drawn from the femoral catheter for blood gas analysis and mice were transcardially 
perfused with 4% PFA.  
Table 1: Neuroscore sheet 
1. General behavior 
Attention Normal searching behavior = 0 point 
Awake, but passive = 1 point 
No spontaneous movement  = 2 points 
2. Cranial nerves status 
Movement of whiskers Present  = 0 point 
Not present = 1 point 
Hearing Present = 0 point 
Ear movements = 1 point 
Not present = 2 points 
3. Motor activity 
Forelegs movement: left Normal  = 0 point 
Stiffened  = 1 point 
Paralyzed  = 2 points 
Forelegs movement: right Normal = 0 point 
Stiffened  = 1 point 
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Paralyzed = 2 points 
Hind legs movement: left Normal  = 0 point 
Stiffened  = 1 point 
Paralyzed = 2 points 
Hind legs movement: right Normal = 0 point 
Stiffened  = 1 point 
Paralyzed = 2 points 
4. Coordination   
Beam walk 3 cm  = 0-4 points 
Beam walk 1.5 cm  = 0-4 points 
Beam walk 1 cm  = 0-4 points 
Criteria: 0 points: normal movement/no failure 
                   1 points: wrong placement of the foot/unstable movements 
                2 points: stay seated/ stays on the beam 
                3 points: falls after a few steps from the beam 
                4 points: falls directly from the beam without further movement 
Floor cross test: Both 
forepaws touch the ground 
when the mouse is lifted by 
the tail  
Present  = 0 point 
Not present  = 1 point 
  
5. Neuroscore (Bederson)  
 No deterioration = 0 point 
Bent forepaws = 1 point 
Reduced resistance of the left side = 2 points 
Circling behavior when pulling the tail = 3 points 
Spontaneous circling = 4 points 
No spontaneous movements = 5 points 
 
 Total score 0-31 points 
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Immunohistochemistry 
2.2.7.4 Antigen retrieval 
Pepsin digestion was used to retrieve the collagen IV antigen as described in the 
literature210. Slices were first submerged in 37°C distilled water for five minutes and 
incubated in pepsin solution for ten minutes at 37°C, then washed in PBS.  
2.2.7.5 DAB staining 
Slices were fixed in acetone for ten minutes. After washing in PBS, slices were 
incubated in 1% H2O2 solution for ten minutes to block endogenous peroxidase 
activity and pretreated in 0.25% PBS-Tween for ten minutes. 3 drops of avidin and 
biotin were applied to block avidin and biotin binding proteins for 15 minutes 
respectively.  
Next, slices were incubated with the following primary antibodies in blocking solution 
for three hours: 
- 1:200 Anti-Ly76 antibody (TER119)   
- 1:200 Anti-collagen type IV antibody 
- 1: 200 Anti-mouse CD45 antibody 
After being rinsed with 0.25% PBS-Tween for ten minutes, slices were then incubated 
in the following secondary antibodies in blocking solution for 30 minutes:  
 -  1:200 Biotinylated goat anti-rabbit IgG antibody  
 -  1:300 Biotin-SP Affinipure F (ab )´2 Fragment mouse anti-rat IgG (H+L) 
After being rinsed with 0.25% PBS-Tween for another ten minutes, slices were 
incubated in ABC solutions (Vectastain, Vector Laboratories, USA) for another 30 
minutes; afterwards DAB solution (3,3’-Diaminobenzidine kit, Vector Laboratories, 
USA) was added. Slices were incubated until the brownish biocytin staining becomes 
visible (three to five minutes) and immediately transferred to water in order to stop 
the reaction. 
Slices were counterstained for nuclei with hematoxylin and dehydrated with an 
increasing concentration of ethanol solution (70%, 96%, 100%).  
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In the end, slices were air-dried for three minutes, embedded with quick-hardening 
mounting medium (Eukitt, O.Kindler, Germany) and covered with coverslips. 
2.2.7.6 Microscopic analysis 
An Axio Imager M2 microscope was used for observation and image recording. For 
immunofluorenscence, an X-cite 120 fluorescence illuminator was used to excite 
FITC-lectin and TMRM dextran. 525-550 nm and 605-670 nm filter sets were used to 
capture each section with a 40x objective. DAB staining were observed and recorded 
by light microscopy. A mosaic scanning tool was used to record the whole section 
with a 20x objective. 
2.2.7.7 Cell and vessel measuring 
For quantification, 8 ROI were selected across both hemispheres on three 
representative sections, as shown in Figure 8. For FITC dextran and TMRM dextran 
analysis, images were collected, transformed to 8-bit and quantified for pixel 
numbers for each ROI. CD45 positive cells were counted per ROI. Pixel numbers of 
TER119 and collagen IV positive cells were quantified using Image J. The ratio of non-
perfused vessels per ROI was calculated by comparing the pixels of TER119 positive 
cells to collagen IV positive cells in each brain. 
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Figure 8: 8 ROIs was selected from three representative sections211: (A) Bregma -1.7mm, (B) 
Bregma -2.54mm and (C) Bregma -2.8mm. The original size of each ROI is 1000 x 1200 pixels 
and 0.8 x 0.67mm.  
2.2.8 Quantification of two photon microscopy images 
2.2.8.1 Vessel measurement 
Vessel diameter was manually measured in randomly chosen Z-stacks. In each 
selected vessel segments, the maximal vessel diameter was measured along a 
distance of 60 to 80μm at more than five positions. Measurement started 15 μm 
away from vessel bifurcations.   
The measurement of vasospasm was carried out by measuring the narrowest 
diameter and the diameters of the two flanking non-spastic vessel segments.  
Several parameters were calculated to quantify the change in vessel diameter. Within 
a measured vessel segment the range percentage of mean describes the variation of 
the vessel diameter.  
 
              
       
    
      
The method of measuring microvasospasms and the formula used for calculations are 
depicted in Figure 9 B. The degree of vasospasm represents the severity of vessel 
constriction. We defined a spastic segment with a vessel constriction more than 15% 
as a vasospasm. Anything less than a variation of 85% was considered as a normal 
variation of vessel diameter. 
The spasticity index is a comparison of the degree of vasospasm at different time 
points. It depicts the changes of the degree of vasospasm over time.   
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Figure 9: (A) Example of a repetitive line scan for blood flow velocity measurement. (B) 
Measurement of microvasospasms and calculation of degree of vasospasm and spasticity 
index. 
2.2.8.2 Perfusion volume 
Imaris software was used to reconstruct the vessels in a 3D stack (607 x 607 x 140 
μm). The total volume of FITC-containing pixels, namely the perfused vessel volume 
after SAH was calculated. Then co-localizing TMRM dextran and FITC dextran 
containing pixels were excluded and the total volume of remaining TMRM dextran-
containing pixels was calculated to quantify the extravasated blood volume.  
Each ROI was divided into a superior layer (0-70 μm) with pial vessels and an inferior 
layer (70-140 μm) with parenchymal vessels. 
2.2.8.3 Blood flow velocity 
Line scan data are represented as space-time images, in which time increases from 
top to bottom over the length of the scanned vessel. As is shown in Figure 9 A, dark 
stripes represent the trajectory of a single erythrocyte. By dividing the scanned vessel 
length (μm) by the respective scanning time (msec), blood flow velocity was 
calculated for arteries, veins and capillaries.  
2.2.8.4 Statistical analysis 
Statistical analyses were performed with SigmaPlot 13.0 software. Normally 
distributed data were compared with the Student t-test, while not normally 
distributed data was compared with the Mann Whitney U test. Differences with p 
values less than 0.05 were considered to be statistically significant.  
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3. Results 
3.1 Clazosentan experiment 
3.1.1 Physiological monitoring 
After SAH induction, ICP rapidly increased because a hematoma formed within the 
rigid skull. ICP went up to values close to systemic blood pressure (Figure 10 A); 
Consequently cerebral perfusion pressure (CPP), which is calculated by subtracting 
ICP from mean arterial pressure (MAP), decreased and immediately caused a 
dramatic drop of regional cerebral blood flow (rCBF) (Figure 10 B). Therefore, the 
brain suffered from global cerebral ischemia for several minutes. Within five minutes, 
ICP values stabilized around 20 mmHg (Figure 10 A) and stayed stable until the end of 
the monitoring period. Regional CBF normalized within ten minutes after hemorrhage. 
There was no significant difference between the Clazosentan and vehicle group.   
Mice were randomly assigned to the Clazosentan or vehicle treatment group and 
intravital microscopy was performed by an investigator blinded to the treatment of 
the animals. Imaging consisted of three different periods: baseline imaging started at 
2.7 hours after SAH, imaging after treatment started at three hours after SAH and 
lasted for 30 minutes, and post-treatment imaging started after cessation of 
intravenous infusion and lasted for 20 minutes.  
During intravital imaging MAP remained within physiological range and was not 
significantly different between groups (Figure 10 C). 
During SAH induction and IVM, body temperature, heart rate, blood pressure and 
peripheral oxygen saturation (SpO2) were within the physiological range and showed 
no significant difference between groups (Table 2). Since increased arterial pCO2 has 
a vasodilatory effect, end-expiratory pCO2 was maintained within the physiologic 
range throughout the whole experiment by adjusting the ventilation frequency. 
Blood gases including pH, pCO2 and partial pressure of oxygen (pO2) were measured 
at the end of imaging and did not show any difference between the groups (Table 2).  
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Figure 10: (A) Intracranial pressure (ICP) rapidly increased over 60mmHg and (B) regional 
cerebral blood flow (CBF) decrease as the middle cerebral artery was perforated. C. 
Continuously measured mean arterial blood pressure (MAP) was not affected by the 
Clazosentan infusion.  
Table 2: Physiological data from Clazosentan experiment. I: MCA perforation surgery, II: 
Imaging period, * p<0.05, ** p<0.01. 
 
 Vehicle (n=7) 
Mean ± SD    
Clazosentan (n=6) 
Mean ± SD    
P-value 
Body temperature (°C) I 37.3 ± 0.09 37.2 ± 0.10 0.162 
Body temperature (°C) II 37.3 ± 0.14 37.2 ± 0.09 0.636 
End tidal pCO2  (mmHg) I 22.6 ± 1.96 23.0 ± 1.07 0.776 
End tidal pCO2  (mmHg) II 20.9 ± 1.04 20.9 ± 0.73 0.792 
SpO2 I 97% ± 1% 96% ± 1% 0.154 
  
49 
SpO2 II 97% ± 1% 97% ± 1% 0.223 
Respiratory Rate (times/min) I 158 ± 6 160 ± 5 0.426 
Respiratory Rate (times/min) II 161 ± 13 166 ± 9 0.537 
Heart Rate (beats/min) I 280 ± 28 251 ± 35 0.663 
Blood Pressure (mmHg)II 76 ± 5 75 ± 5 0.432 
pH 7,31 ± 0,03 7,27 ± 0,03 0.248 
pCO2 (mmHg) 36,2 ± 3,19 34,7 ± 1,67 0.305 
pO2 (mmHg) 106,2 ± 10,79 108,4 ± 7,99 0.456 
 
 
Figure 11: (A) Clazosentan does not relieve microvasospasm after SAH. The number of 
vasospasms as well as the spasticity index in both small-caliber (diameter 9.5-25 μm) (B) and 
large-caliber vessels (diameter >25 μm) (C) relative to baseline are not affected during 
treatment with Clazosentan or vehicle.  
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3.1.2 Microvasospasms of the pial arterioles during imaging 
Three hours after MCA perforation, narrowing of cerebral arterioles, namely 
microvasospasms were observed under the 2PM (Figure 16 C). The amount and 
degree of constriction is consistent with previous studies77 78 . As illustrated in Figure 
11 A, as soon as treatment with Clazosentan or vehicle started, the number of 
microvasospasms decreased by 20% compared to baseline in both groups. This effect 
could be due to the relatively rapid increase in total blood volume by the bolus 
injection. Thereafter the number of microvasospasms stayed in the same range 
throughout the treatment and post-treatment period and was not affected by 
Clazosentan treatment. Similarly, also the spastic index of small and large 
microvessels was not affected by infusion of Clazosentan (Figure 11 B and 11 C, 
respectively). Additionally, Clazosentan did not show any significant effect on the 
diameter of small nor large non-spastic vessels (Figure 12 A and B, respectively). This 
indicates that the selective blocking of the ETA receptor does not relieve acute 
constriction of microvessels, suggesting the mechanism behind microvasospasm is 
different from that of macrovasospasm.  
 
Figure 12: (A) Clazosentan does not affect the diameter (relative to baseline) of both small-
caliber (B) and larger-caliber non-spastic vessel segments in mice treated with Clazosentan 
or vehicle. 
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3.2 Cisterna magna injection 
3.2.1 Establishment of CMI model 
A CMI model with a perivascular blood distribution pattern and without interference 
of the cerebral hemodynamics was established.   
Table 3: Physiological data from CMI experiment. I: Surgical period of cisterna magna 
injection, II: Imaging period, * p<0.05, ** p<0.01 
 aCSF (n=5) 
Mean ± SD    
Blood (n=8) 
Mean ± SD  
p-value 
Body temperature (°C) I 37.2 ± 0,03 37.3 ± 0.13  0.236 
Body temperature (°C) II 37.3 ± 0,13 37.3 ± 0.26 0.949 
End tidal pCO2  (mmHg) II 21.0 ± 2.15 22.1 ± 1.78 0.868 
SpO2 I 87% ± 7%  86% ± 4%  0.730 
SpO2 II 96% ± 1% 97% ± 1%  * 
Respiratory Rate (times/min) II 197 ± 9 174 ± 23 0.192 
Heart Rate (beats/min) I 369 ± 14 340 ± 39  0.168 
Blood Pressure (mmHg)II 72 ± 3  79 ± 11 0.810 
pH 7.27 ± 0.02 7.32 ± 0.06 0.140 
pCO2 (mmHg) 44.6 ± 1.44 40.3 ± 7.93 0.931 
pO2 (mmHg) 95.16 ± 7.10 106.9 ± 11.18 * 
pH of aCSF 7.39 ± 0.03 - - 
 
3.2.1.1 Physiological monitoring 
Freshly prepared aCSF (pH=7.4) and heparinized blood were injected into the CSF via 
the cisterna magna. Physiologic parameters including body temperature, heart rate, 
blood pressure and SpO2 were recorded during the CMI and the IVM imaging. All 
parameters were within the physiological range and there were no significant 
differences between groups expect for SpO2 and pO2 (Table 3). SpO2 is slightly lower 
than the normal range during the surgical period of cisterna magna injection. This 
may be explained by the positioning of the mouse during the injection. The head 
needed to be bended by 120 ° in order to stretch the atlanto-occipital membrane and 
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expose the cisterna magna 205 212. Bending of the head may affect the normal 
breathing pattern thereby resulting in reduced oxygen saturation. The difference, 
however, was so small that the effect may not be biologically relevant. There was 
also a significant difference between both groups in the blood oxygenation status at 
the end of the experiment.  We cannot exclude the possibility that this is caused by 
the direct stimulation of the respiratory center around the pons and medulla during 
injection. Since both SpO2 and pO2 are within the physiological range, the difference 
between both groups should not have a big influence on our readout.  
3.2.1.2 Blood distribution pattern and hemodynamic changes 
After injection of 20 μl blood into the cisterna magna, animals were transcardially 
perfused with saline and 4% PFA. The brain was removed and observed under a light 
microscope. In theory, injected blood spreads across the whole ventricular system. 
On the brain surface, we found blood deposits in the cisterna magna, the gyrus of the 
cerebellum, and along the superior sagittal sinus (Figure 13 A and B) as well as along 
the pial arteries of both hemispheres (Figure 16 B). With 2PM, the blood distribution 
of the injected blood could be observed with higher resolution: the FITC signal was 
detected along pial vessels as well as inside cell-like structures which were located 
within the subarachnoid space (Figure 13 C). In the brain parenchyma, the FITC signal 
was detected in the perivascular space around penetrating arterioles and capillaries 
(Figure 13 D).  
We measured CBF and blood flow velocity as indicators for changes of cerebral 
hemodynamics. A slight increase of regional CBF after the injection was observed 
(Figure14 A) in both groups. This could be a result of a transient and slight increase in 
ICP. Blood flow velocity was measured by line-scan during two-photon imaging and 
did not differ between groups in all investigated vessel categories (Figure 14B). 
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Figure 13: (A) Gross anatomy picture shows blood distribution on cortices of a brain after 
cisterna magna injection of blood, red arrow indicates the location of CMI. (B) Blood 
distribution on the ventral side of the brain after injection of blood. (C) Exemplary two-
photon image of a superficial cerebral artery. Injected FITC can be detected along both sides 
of the vessels (white arrows) and also accumulated in cell-like structures (red arrows). (D)   
Exemplary two-photon image at the level of the brain parenchyma. White arrow indicated 
perivascular FITC dextran distribution around a penetrating artery. Red arrows indicate FITC 
dextran accumulating around capillaries.   
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Figure 14: (A) Increase of regional CBF after cisterna magna injection of blood and aCSF. (B) 
Blood flow velocity in arteries, veins and capillaries: no significant difference was detected 
between both groups.  
 
Figure 15: (A) The number of microvasospasms was increased in the blood injection group. 
(B) There is no significant difference in vessel diameter variability between both groups in 
different vessel categories. 
3.2.1.3 Microvasospasms of pial arterioles 
Two ROIs were recorded during IVM imaging. Three hours after cisterna magna 
injection, pearl-string like vasoconstrictions were observed in the blood injection 
group (Figure 16 D). As shown in Figure 15 A, the blood injection group had 
significantly more microvasospasms compared to the aCSF injection group. When 
looking at the variance of the vessel diameter, there is a trend that the aCSF group 
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has less variance, however, there is no significant difference between both groups. 
We think that incorporation of non-spastic vessel segments might dilute the 
significant difference found in the number of spastic vessel segments.  
3.2.2 Comparison between CMI and perforation model 
The induction of SAH by endovascular perforation is a well-established SAH mouse 
model which mimics the natural course after aneurysm rupture. Severe 
microvasospasms can be observed by intravital microscopy (Figure 16 C). As 
described previously massive perivascular blood distribution on the surface of 
perfused brains especially along the branches of the MCA were observed (Figure 16 
A)213.  Moreover, by observing SAH brain slices that were stained with FITC lectin and 
TMRM dextran for extravasated blood, we found that also penetrating arterioles 
were surrounded by perivascular blood (Figure 17 A and C). A similar distribution 
pattern as well as microvasospasms was present in the cisterna magna blood 
injection model (Figure 16 D). Blood injected into the cisterna magna spread onto the 
surface of the cortex and distributed along the branches of the MCA on both 
hemispheres (Figure 16 B and Figure 17 B and D).  
In terms of hemodynamic changes, unlike in the perforation model, injection of blood 
into the cisterna magna did not induce a decrease in CBF (Figure 18 A). In addition, 
three hours after injection of blood or aCSF, blood flow velocity did not differ 
between both groups (Figure 18 B and C).  
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Figure 16: (A) and (B) Gross anatomy of middle cerebral arteries branches of perfused brains. 
Extravasated blood distributed around pial vessels in the perforation model (A). Less 
perivascular blood were seen in the cisterna magna blood injection model (B). (C) and (D) 
Microvasospasms (white arrows) were observed in both the perforation SAH model (C) and 
the cisterna magna blood injection model (D).  
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Figure 17: (A) An exemplary immunofluorescet picture of a penetrating arteriole from a 
mouse subjected to perforation SAH. FITC lectin (green) stains the vessel wall and TMRM 
(red) marks extravasated blood. (B) An exemplary two-photon image showing a superficial 
arteriole from a mouse subjected to cistern magna blood injection. TMRM dextran marks 
the vessel lumen and FITC dextran labels injected blood. (C) and (D) Fluorescence intensity 
was measured along the white lines depicted in (A) and (B). In (C), the FITC signal peak 
represents the arterial lumen and TMRM signal accumulates in two smaller peaks on both 
sides of the arterial lumen, representing perivascular blood distribution. The pattern is 
comparable in (D), TMRM signal shows the vessel lumen, and FITC is located on both sides of 
the arterial lumen, representing perivascular distribution of injected blood. 
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Figure 18: Quantification of hemodynamic changes in the perforation model and cisterna 
magna injection model. (A) In the perforation model, CBF dramatically decreased after 
arterial perforation (red dashed line) compared to baseline and recovered to pre-perforation 
levels in about three to four minutes. In the blood CMI model, CBF increased a little after 
injection (red dashed line) at the 30 seconds and 1 minute time points, then stays around 
pre-injection levels until the end of the observation period. Blood flow velocity after 
perforation SAH was significantly lower than after cisterna magna injection (B) and (C) and 
did not differ between blood and aCSF injection groups. 
3.3 Deferoxamine experiment 
3.3.1 Physiological monitoring 
Intravenous infusion of DFO or vehicle was done in a randomized fashion before SAH. 
After penetration of the MCA, ICP rapidly increased (Figure 19 A) and regional CBF 
(rCBF) significantly decreased (Figure 19 B). Within 5 minutes, ICP dropped but still 
remained on a higher plateau until the end of the monitoring period. Regional CBF 
normalized within ten minutes after the perforation. There was no significant 
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difference between the DFO and vehicle group regarding ICP or rCBF (Figure 19 A and 
B). 
Physiologic parameters including body temperature, heart rate, blood pressure and 
SpO2 were recorded during SAH induction and IVM imaging. All monitored 
parameters and blood gases measured at the end of the imaging were in the 
physiologic range and did not show a difference between groups except for heart 
rate (Table 4). During SAH induction, heart rate is higher in the DFO group compared 
to the vehicle group (Table 4). We postulate that this could be a systemic side effect 
of DFO. Intravenous infusion of DFO was associated with mild hypotension214, thus 
for compensation heart rate may increase. Because of the interference with the 
cardiovascular system, the filament needed to be inserted several times in the DFO 
group (Figure 19 C) in order to release the same amount of blood into the 
subarachnoid space and causes a comparable increase in ICP (Figure 19 D).   
 
  
60 
Figure 19: (A) Intracranial pressure (ICP) rapidly increased to around 60 mmHg and regional 
cerebral blood flow (rCBF) decreased after perforation of the MCA (B). In order to reach 
more or less the same level of peak ICP (D), the filament needed to be reinserted several 
times in the DFO group (C).  
Table 4: Physiological data from DFO experiment. I: Surgical preparation of SAH, II: Imaging, 
* p<0.05, ** p<0.01. 
 Vehicle (n=8) 
 Mean ± SD    
DFO (n=8) 
Mean ± SD   
p-value 
Body temperature (°C) I 37.1 ± 0.10 37.1 ± 0.07  0.398 
Body temperature (°C) II 37.1 ± 0.07 37.1 ± 0.08 0.798 
End tidal pCO2  (mmHg) I 21.1 ± 0.54 21.1 ± 0.95 0.382 
End tidal pCO2  (mmHg) II 20.2 ± 0.70 19.9 ± 0.71 0.234 
SpO2 I 94% ± 2%  93% ± 2%  0.721 
SpO2 II 96% ± 1% 96% ± 3% 0.442 
Respiratory Rate (times/min) I 145 ± 7 144 ± 3 0.803 
Respiratory Rate (times/min) II 142 ± 7 141 ± 8 0.793 
Heart Rate (beats/min) I 260 ± 23  353 ± 13  ** 
Blood Pressure (mmHg)II 73 ± 6  67 ± 7  0.078 
pH 7.27 ± 0.03 7.26 ± 0.03 0.267 
pCO2 (mmHg) 44.2 ± 3.83 42.3 ± 6.78 0.499 
pO2 (mmHg) 95.7 ± 13.83 101.4 ± 18.90 0.500 
 
3.3.2 Vessel quantification and hemodynamic changes 
Three hours after MCA perforation, microvasospasms were observed with the 2PM. 
As illustrated in Figure 20 A, the total number of microvasospasms was significantly 
decreased in DFO treated animals, especially no microvasospasms were found in 
arterioles with a diameter larger than 30 μm. The degree of vasospasm in the 
remaining vessels did not differ between groups (Figure 20 C). Since we hypothesized 
that DFO may relieve vasoconstriction by chelating iron, we quantified the number of 
vasospasms found in vessels with or without blood distributed around them. We 
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found that DFO resolved microvasospasms mainly in larger vessel (Figure 20 C) which 
were covered with blood (Figure 20 B), suggesting that DFO relieves 
microvasospasms only at sites where blood is present. In smaller-sized vessel 
segments, there is no significant difference between both groups, though there is a 
trend that the DFO group shows less variance in vessel diameter (Figure 20 D).  
Considering that vasoconstriction may cause insufficient perfusion after SAH which 
could be compensated by an increase of blood flow velocity, we compared blood 
flow velocity and the perfusion volume of parenchymal vessels after SAH in both 
groups. Neither of them showed a distinguishable difference between groups in all 
observed vessel categories (Figure 21). We postulate that even though the iron 
chelating effects of DFO reduced the occurrence of vasospasm, the systemic 
cardiovascular side effect of DFO may have masked the expected improvement in 
cerebral blood flow.  
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Figure 19: DFO relieved microvasospasm after SAH. (A) The number of vasospasms was 
reduced in the DFO treated group primarily in vessel segments that were covered with blood 
(B). Though the degree of vessel diameter variability does not differ between both groups, 
no vasospasms were found in arteries larger than 30μm (C). Among all measured vessels, 
there is no significant difference in range percentage of mean between both groups.   
 
Figure 21: There is no significant difference in blood flow velocity (A) and perfusion volume 
(B) between the DFO and vehicle treated group. 
3.3.3 Characteristic of blood distribution and investigation of erythrocytes and 
leukocytes after SAH 
In order to investigate the blood distribution pattern in the perforation model, two-
photon microscopy images were 3D reconstructed and divided in a superior layer (0-
70 μm) containing pial vessels and an inferior layer (70-140 μm) containing 
parenchymal vessels. In most images we observed three patterns of blood/TMRM 
dextran distribution: around superficial vessels, along penetrating vessels (Figure 22 
A and C) and a dotted accumulation under the dura mater (Figure 22 B). 
Quantification of extravasated blood in both layers showed that the majority of blood 
accumulated within the subarachnoid space, whereas only a small amount of the 
plasma marker TMRM dextran penetrated into the parenchyma (Figure22 D) 
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Figure 20: Exemplary 3D reconstructed two-photon images from two ROI (A, B and C) 
showing blood distribution patterns and the quantification of extravasated blood in superior 
(B) and inferior (C) layer. Extravasated blood distributed along vessels (white arrows in A and 
C) or accumulated in a dotted pattern (yellow arrows in B). It mainly distributes in the 
superior layer, only a small amount of blood penetrates deep into the parenchyma (D). 
In order to further investigate this issue we applied TMRM dextran before SAH. It 
stains extravasated blood and labels non-perfused vessels after SAH. FITC lectin 
injected before sacrifice stains still perfused vessels after SAH. Non- or incompletely 
perfused vessels accounted for 4% of all observed vessels. There was no significant 
difference between hemispheres suggesting that microvascular perfusion deficits are 
a global phenomenon. (Figure 23) 
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Figure 21: (A) An exemplary fluorescent section shows the damaged right hemisphere (white 
arrow) caused by removal of the ICP probe. TMRM dextran (red) stains extravasated blood 
and non-perfused vessels after SAH (A & B). FITC lectin (green) stains walls of perfused 
vessels (A & B). (B) A magnification of the cortical vessels (white frame in A). Large amount 
of non-perfused and incompletely perfused vessels (FITC and TMRM signal overlap) were 
found. (C) Quantification of total coverage of FITC lectin and TMRM dextran signal and their 
overlapping areas. No significant difference was found between both hemispheres (n=7). 
TER119 stains erythrocytes therefore vessels positive for TER119 after perfusion 
fixation suggest a lack of perfusion at that specific time point. Collagen IV stains the  
vascular extracellular matrix and may therefore be used to stain the whole cerebral 
vasculature, i.e. perfused and non-perfused vessel segments (Figure 24). Consistent 
with our findings using plasma markers (Figure 23 C), the quantification using TER119 
showed about 4% of non-perfused vessels after SAH. TER119 positive vessels did not 
differ between both hemispheres (Figure 24 C). 
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Since leukocyte may get stuck in capillaries and may therefor contribute to the “no -
reflow” phenomenon215, we investigated the number of capillary leukocytes after 
SAH by CD45 staining. In a previous in vivo study from our group, sticking and 
plugging leukocytes were observed in the microcirculation three hours after SAH213. 
In the current study we tried to find the presence of leukocytes in perfused brain 
sections. With DAB staining, only a very small amount of CD45 positive cells were 
found three hours after SAH (Figure 25 A). There was no significant difference 
between hemispheres (Figure 25 B).  
 
  
66 
Figure 22: Exemplary DAB staining shows dotted or linear TER119 positive cells (A) and 
Collagen IV positive vasculature (B) TER119 positive cell coverage length does not differ 
between both hemispheres (C).  
 
Figure 23: (A) Exemplary DAB stained section shows CD45 positive cells. (B) The number of 
CD45 positive cells per mice does not differ between both hemispheres.  
4. Discussion 
4.1 Comprehensive summary of the results 
SAH is a subtype of hemorrhage with a very high mortality and disability rate which 
mainly affects people at working age. So far, there is no effective treatment to 
decrease in hospital mortality and improve patients’ functional outcome.  
Cerebral ischemia is the key factor in the pathophysiology of SAH. However the 
mechanisms causing cerebral ischemia after SAH are still unclear. Clinical and 
experimental studies have focused on the mechanisms of delayed cerebral ischemia 
(DCI) for several decades, however, we and other demonstrated that microcirculatory 
dysfunction occurs already within minutes after SAH and that this process  may be 
the root for cerebral ischemia as well as other pathophysiological processes resulting 
in brain injury after SAH216. In particular, our group aimed to understand the 
mechanisms of acute pial artery constriction, namely microvasospasm, which was 
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shown to be responsible for early cerebral ischemia after SAH78. The 
pathophysiological process of microvasospasms and related microcirculatory 
dysfunction in EBI has not been investigated to date. By making use of two-photon in 
vivo microscopy (2PM), we are the first ones to conduct in vivo pathomechanistic 
research in early microcirculatory dysfunction after SAH.  
In this thesis I investigated the pathomechanism underlying acute microvasospasms 
after SAH. Since endothelin (ET) A receptors play an important role for the formation 
of large artery spasms and DCI, we investigated whether these receptors are also 
responsible for acute microvasospasm formation by using the ETA receptor antagonist 
Clazosentan. We found that inhibition of ETA receptors does not change the number 
or degree of microvasospasm, therefore ETA receptors do not seem to be involved in 
the development of microcirculatory dysfunction after SAH.  
The outcome after SAH is determined by the acute global ischemia occurring 
immediately after the bleeding and the impact of extravasated blood on cerebral 
vessels, i.e. acute microvasospasms. In order to identify the mechanism of acute 
microvascular constriction after SAH without the confounding effects of global 
cerebral ischemia, we established a cisterna magna injection mouse model which 
mimics the blood distribution pattern of the MCA perforation model without causing 
global cerebral ischemia. With this newly developed model we were able to 
investigate the consequences of blood in the subarachnoid space without the initial 
increase in ICP which causes global cerebral ischemia and cannot be avoided in the 
vessel perforation model.  
Therefore we were able to isolate the effect of different blood components in the  
subarachnoid space from the impact of rapidly increasing ICP and reduced blood flow 
directly after the bleeding. By using the cisterna magna blood injection model we 
found that injection of autologous blood but not artificial CSF into the subarachnoid 
space induces microvasospasm. However the vessel constrictions were not as severe 
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as in the filament perforation model and did not induce a drop of cerebral 
parenchymal perfusion.  
In order to tease out which blood components induce acute vessel constriction we 
further tested the effect of the iron chelator Deferoxamine on microvasospasms 
three hours after experimental SAH. Our data show that application of Deferoxamine 
before SAH decreases the number of microvasospasms and relieves vasoconstriction 
in those pial arterioles that are covered with blood and have a diameter of 30 μm or 
more. This suggests that iron released from burst erythrocytes plays an important 
role in the formation of microvasospasms. 
Taken together, we demonstrated that the ETA receptor antagonist Clazosentan 
neither affects the number nor the severity of microvasospasms, suggesting that ETA 
receptor are not involved in the formation of microvasospasm. Further, we described 
the characteristic of blood distribution after MCA perforation and cisterna magna 
injection in mice. Perivascular blood distribution is commonly observed and most of 
the blood stays on the surface of the brain instead of draining down into the 
parenchyma along the paravascular space (PVS). We believe that blood and its lysates, 
especially free iron, are potential culprits for acute vasoconstriction which interfere 
with the microcirculation and lead to early cerebral ischemia after SAH. Moreover, 
we show that the iron chelator Deferoxamine relieves microvasospasm after MCA 
perforation in mice, indicating that free iron plays an important role in the formation 
of microvasospasms. Future investigations are required to unravel the role of 
different hemolysis products in the pathomechanisms during EBI after SAH.   
4.2 Clazosentan does not relieve microvasospasm in EBI after SAH 
Delayed vasospasm has long been considered to be the key factor in DCI. Therefore 
reversion of arterial spasm was thought to be a promising therapeutic target for 
improving patients’ neurological outcome after SAH. Several experimental studies 
identified the ETA receptor antagonist Clazosentan as an effective vasodilator
217 218. In 
a large phase two clinical trial53 known as CONSCIOUS-1 (Clazosentan to Overcome 
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Neurological Ischemia and Infarction Occurring after Subarachnoid Hemorrhage), 
Clazosentan significantly relieved SAH induced angiographic vasospasms in patients. 
Based on these results, we hypothesized that ETA receptors may also be involved in 
the pathogenesis of early microcirculatory dysfunction. This hypothesis was 
supported by investigations showing that endothelin was not only elevated during 
delayed angiographic vasospasm129 130 , but already elevated early after experimental 
SAH219 220.  
Our results show that pharmacological inhibition of ETA receptors by Clazosentan 
does not affect the number and severity of microvasospasms, as well as the degree of 
global microvascular constriction after SAH. Moreover, data from the same series of 
experiment three days after SAH shows no significant difference in neurological 
outcome between vehicle and drug treated animals221. Therefore we conclude that 
microvasospasms do not depend on ETA receptors. These data show that the 
mechanisms inducing large vessel spasm are different from those causing 
microvasospasm formations. Our findings are consistent with other studies showing 
that Clazosentan has no effect on microthrombosis, endothelial NO synthase 
expression, and neuronal cell death after SAH146 222 223. Although pharmacologic and 
pharmacokinetic characteristic of Clazosentan has been studied in detail in rodents144 
217 218, we cannot exclude the possibility that some unrevealed side effects of 
Clazosentan may neutralize the beneficial effect of ETA receptor inhibition. However 
it is most likely not the case because tight monitoring of a whole range of physiologic 
variable did not reveal any systemic side effects of Clazosentan in our experimental 
series.  
Our experiments also confirmed the presence of microarterial constrictions starting 
three hours after SAH78 and the fact that microvasospasms are associated with a 
severe reduction of parenchymal perfusion and impaired functional outcome after 
SAH213 224. Our findings corroborate clinical data showing that Clazosentan did not 
improve outcome after SAH. These findings further highlight the importance of 
restoring normal microcirculatory function after SAH and explain the failure of the 
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CONSIOUS trials: inhibition of ETA receptors did not affect cerebral microcirculatory 
perfusion, thus ischemia and neurological outcome were not ameliorated.  
4.3 Distribution and characteristic of extravasated blood and non-perfused 
vessels in perforation SAH model 
A previous study from our group showed that a 20% reduction of pial arteriolar 
diameter caused by microvasospasms results in a 60% reduction of parenchymal 
perfusion after SAH in mice213. Based on these findings, we hypothesize that relieving 
microvasospasm will represent a promising therapeutic target for the prevention of 
brain injury after SAH. In order to develop such an effective therapeutic approach, we 
decided to explore the mechanism underlying the formation of microvasospasm after 
SAH.  
Since it is essential to clarify the blood distribution pattern after SAH in order  to 
understand the structural etiology behind microvasospasm, we investigated the 
distribution character of extravasated blood after perforation SAH in detail. Three 
hours after the arterial perforation, a larger amount of subarachnoid blood 
distributed along pial vessels, whereas a smaller amount invaded into the 
parenchyma along penetrating arteries through the perivascular space (PVS), a 
continuous space surrounding cerebral vessels connecting arteries, capillaries and 
veins225 226. The PVS is the anatomic correlate of the glymphatic system, a drainage 
system using the CSF to clear interstitial solutes from the brain227 228. Our finding is 
consistent with a previous histological report showing the presence of blood draining 
within the brain parenchyma after SAH in mice229. In addition to these previous 
findings we used a tracer based method to indeed prove that subarachnoid blood 
enters the brain parenchyma after SAH and quantified and compared the volume of 
intraparenchymal blood. Our data demonstrate that there is an order-of-magnitude 
difference between the amount of blood found on the surface of the brain as 
compared to the amount found within the brain parenchyma. This observation may 
be explained by the limited capacity of the PVS to transport blood together with an 
impaired CSF circulation after SAH. Only molecules with a size of less than 100 kDa 
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may enter the PVS. The permeability of the PVS has also been shown to be changed 
after SAH228 229. This is in agreement with experiments showing that the glymphatic 
flow is severely impaired already two hours after SAH in the macaca facicularis and is 
associated with perivascular blood clots230.  
Our group previously found that 30% of spastic pial arterioles were occluded by 
microthrombosis three hours after SAH. In the current study investigating 
microthrombosis within the brain parenchyma by examining TMRM dextran marked 
vessels and the ratio of TER119 positive cells to Collagen IV stained vasculature at the 
same time point we found only 4% not perfused vessels. Based on the fact that the 
expression of collagen IV in basal lamina starts to decrease three hours after SAH231, 
the actual percentage of non-perfused vessel could even be lower. These numbers 
are in contrast with a study using the blood injection model, where 15% of 
parenchymal vessels were reported to be not perfused under 2PM232. This 
discrepancy between the in vivo tracer study and the histological studies may be 
explained by the fact that most of the not perfused vessels observed in vivo are not 
completely blocked and may therefore be flushed open by transcardial perfusion.  
In addition to microthrombosis also leukocytes may be important factors for 
microcirculatory dysfunction after SAH. They were found in the CSF of SAH patients 
and in the subarachnoid space of SAH animals from day one to three after the 
bleeding233 234. Recently more studies started to look into leukocyte migration into 
the brain parenchyma shortly after SAH. A prominent amount of neutrophil is 
accumulating in the cerebral microcirculation already ten minutes after SAH and is 
believed to play a role in early vascular injury155. Leukocytes were shown to roll and 
stick inside pial venules and interact with platelets two hours after SAH112. Del Zoppo 
et al. reported that leukocytes which are sticking inside capillaries can block perfusion 
and are involved in formation of microthrombi215.  A previous study from our group 
presents a small amount of leukocyte plugging in parenchymal capillaries213. Our 
immunohistological results demonstrate a consistent finding that not many CD45 
positive cells migrate into the parenchyma in the early phase after the bleeding. Our 
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data of perivascular blood distribution, non-perfused vessels and CD45 positive cells 
suggest that cerebral vasculature is undergoing pathological changes which are 
caused by nearby extravasated blood.  
4.4 Cisterna magna injection model 
The endovascular perforation SAH model is the best available animal model to mimic 
the rupture of an intracranial aneurysm, though it has the inherent shortcoming that 
the bleeding volume cannot be controlled. Another commonly used SAH model, the 
cisterna magna blood injection model, does not mimic aneurysm rupture, but has the 
advantage that ICP and blood volume can be tightly controlled.  
In the perforation SAH mouse model, immediately after perforation of the circle of 
Willis ICP rises close to arterial blood pressure. Concomitantly, CPP drops and CBF is 
reduced by over 80%79. In the cisterna magna blood injection mouse model, a 50 μl 
injection of blood over 15 seconds induces an immediate ICP increase up to 100 
mmHg which also goes along with a severe decrease of CBF235. Both animal models 
are widely used and both exhibit initial perfusion deficits during the bleeding.  
In the current study we aimed to establish a model that mimics the blood distribution 
pattern of SAH but does not cause early perfusion deficits in order to investigate the 
role of blood on the cerebral microcirculation without the confounder of a previous 
global ischemic insult.  
We injected 20 μl of blood into the cisterna magna over three minutes. This 
procedure induced only a slight change of ICP while sufficient perivascular blood was 
present in the brain after perfusion fixation. When we added the plasma marker FITC 
dextran to the injected blood we were able to investigate the distribution of the 
injected blood by intravital fluorescence microscopy. This allowed us to investigate 
for the first time the distribution of blood in the subarachnoid space. Surprisingly, the 
blood did not distribute homogenously within the subarachnoid space, but it spread 
preferentially along subarachnoid arteries. This finding shows that the subarachnoid 
space is not an open space which allows free diffusion of liquids, but that it is 
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compartmentalized and allows liquids to spread preferentially along vessels, more 
specifically, along arteries. More importantly for the context of the current study, we 
were able to show that distribution of blood within the subarachnoid perivascular 
space leads to the formation of microvasospasm. In shape and distribution these 
microvasospasms were identical to microvasospasms observed in the filament 
perforation SAH model and in humans. Since cisternal blood does not induce a drop 
in CBF we can conclude that post-hemorrhagic microvasospasms are induced by peri-
vascular blood and not by the global ischemia which occurs immediately after SAH. 
This conclusion is further supported by the fact that number and severity of 
microvasospasms found after SAH seem to depend on the amount of perivascular 
blood, since we found significant more arteriolar vasospasms in the vessel 
perforation model of SAH, which displays more perivascular blood, than in the blood 
injection model where only 20 μl were injected. Less perivascular blood may 
represent a lower burden for the local Hb scavenging systems and may interfere less 
with the clearance capacity of the glymphatic system. Accordingly, the reduction of 
perivascular blood may represent a valid therapeutic target for the treatment of SAH. 
One shortcoming of the current experiments was that we flushed the catheters used 
to inject the blood into the cisterna magna with heparin. It is known that already a 
low dose of heparin is able to bind Hb and inflammatory molecules and may 
therefore mitigate vasospasm after SAH236-238. Future studies using different 
anticoagulants may help to further improve this model.  
In summary, the CMI model is easy to perform and highly reproducible. It does not 
lead to a decrease in CBF, but has a similar blood distribution pattern as the 
perforation SAH model. Therefore it is very well suited to investigate the 
pathomechanisms of microvasospasms after SAH. 
4.5 Deferoxamine relieves microvasospasm in EBI after SAH 
Topical application of erythrocyte lysates causes immediate severe basilar arterial 
spasms and vasoconstriction of pial arteries96 168 After SAH free blood is effectively 
  
74 
eliminated by microglia117. The degradation works through the CD163-Hp-Hb system 
and the intracelluar enzyme HO-1, which degrade Hb into bilirubin, carbon monoxide 
and free iron. Iron is also found to be immediately released from hemoglobin during 
the lysis of erythrocytes239. Beside its direct cytotoxicity, free iron has been shown to 
activate oxidation reaction and generate reactive oxygen species which contribute to 
the formation of cerebral arteriolar vasoconstriction195 240. 
After SAH in patients, free iron is detected in the CSF one day after the bleeding and 
keeps increasing for at least 5 days.241 242 Iron chelators have successfully been shown 
to reduce oxidative stress, neurodegeneration and delayed arterial vasospasm after 
SAH194-198 214 243 244.  We now aimed to investigate the effect of iron chelation on the 
formation of microvasospasms during EBI after SAH. Our data demonstrate that 
Deferoxamine (DFO), a water soluble iron chelator, reduced vasospasm only in larger 
arterioles which were surrounded by extravasated blood following SAH. This suggests 
that hemolysis induced iron overload plays an important role in the formation of 
microvasospasm. Since this effect was only observed in vessels larger than 30 μm 
these findings also indicate that the mechanisms underlying vasospasm in larger 
arterioles and capillaries are different. 
The only difference between the vehicle and DFO treated animals was a significant 
increase of heart rate in the DFO group during the surgery. We believe that the 
increase in heart rate is a compensatory response to the known mild blood-pressure-
lowering effects induced by intravenous application of DFO214. We measured blood 
pressure in both groups and found no significant effect at the time of imaging, 
however, in order to reach the target peak ICP the filament needed to be reinserted 
several times in the DFO group. Since the peak ICP after MCA perforation depends on 
systemic blood pressure we assume that the MAP was lower in the DFO group during 
the time of SAH induction. This side effect of DFO could explain why there were no 
differences in both blood flow velocity and perfused vessel volume between the DFO 
and vehicle group even though DFO reduced the number of vasospasm. Additionally, 
DFO has a direct cellular toxicity and can cause severe toxicity in normal-dose-
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patients with a low iron burden245. Moreover different studies showed that hemin 
could bind to DFO and together promote protein oxidation and generate cytotoxic 
radicals250-252. Even though in the current study DFO was used as a tool for 
mechanistic research, these possible side effects of DFO need to be considered.  
Our data using DFO suggest that blood which extravasates after SAH into the 
subarachnoid space distributes within the perivascular space of pial vessels and then 
penetrates into the brain parenchyma. In vitro experiments showed that 
pretreatment with DFO could prevent erythrocyte membrane damage and hemolysis 
by reducing lipid peroxidation246. In our current study, we injected DFO systemically 
before SAH to ensure that the drug evenly distributes in the subarachnoid space 
together with the extravasated blood. As soon as hemolysis starts, released free 
ferric iron is scavenged by DFO and iron mediated molecular reactions are most likely 
completely prevented. DFO mainly binds ferric iron, while ferrous iron catalyzes 
reactive oxygen species formation and is considered to be more toxic than the ferric 
form. Contrary to this Fox et al. showed that topic application of ferric iron causes 
mild cerebral arterial vasoconstriction whereas ferrous iron solution causes no 
changes247. Almost all studies investigating the vasospasm relieving effect of both 
ferrous and ferric iron chelators were performed in large arterial vasospasm models. 
According to our results, the ferric iron chelator DFO showed the ability to relieve 
microvasospasms during EBI after SAH and that this is most probably due to its iron 
chelating effect. In combination with the CMI model we established, further studies 
aiming at identifying the therapeutic effect of DFO will reveal important findings on 
the pathomechanisms behind microvasospasms. 
4.6 Conclusion 
In summary, our data show that after SAH, the majority of extravasated blood 
distributed along pial vessels, only a small amount penetrated into the brain 
parenchyma via the perivascular space. Relieving microvasospasm is the key to 
maintain the normal function of the cerebral microcirculation and improve outcome 
after SAH. Our current data show that the development of microvasospasm after SAH 
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does not depend on ETA receptors but is related to the hemolysis product ferric iron. 
Meanwhile, without ICP induced initial cerebral ischemia, a small amount of 
perivascular blood components alone can cause microvasospasm within hours. In the 
future this CMI model can be used for in vivo studies of vasospasm and the 
pathomechanisms that cause microvascular dysfunction after SAH.   
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